ASCP ANNUAL MEETING
LOEWS MIAMI BEACH HOTEL
MAY 29–JUNE 2, 2017

SERVING THE NEEDS
OF THE DIVERSE POPULATION
Dear Colleagues,

Welcome to Miami Beach!

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our very exciting annual meeting. I want to thank both the Program Committee and the Steering Committee for their wonderful work putting together an extraordinary meeting. Our meeting includes not only a very stimulating Latin American Satellite Symposium but also the 25th iteration of our very successful New Investigators’ Program. Our meeting has something for everyone. There are sessions that discuss innovation across not only syndrome-states and the life cycle but also in terms of public-private partnerships, teaching, as well as public health and dissemination research. And just when you think there could be nothing more to entice you out of the Florida sun, there are talks on the challenges posed by medical marijuana, to the role of technology in research and clinical practice to a special workshop on Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields. This year, we have added the Early Career Luncheon with panelists from diverse career trajectories, an FDA 101 Session, and a NIH Diversity Supplement Session. We have also renamed the Federal Agency Directors Plenary (formerly NIH Directors Plenary) and included additional federal agencies such as the Department of Defense and Patient-Centered Outcomes Research Institute. There is, of course, the very important and unique Regulatory Session that traditionally serves as the closing session of our meeting.

The ASCP is committed to finding and testing new therapies for our patients. We want to advance not only the field of psychopharmacology but treatment research in general. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials. I am sure that we will see presentations and posters at this meeting that will become important methods for caring for our patients in the future.

Our society has taken on a new responsibility in the past year and is actively becoming one of the places that legislators, federal agencies, and other groups interested in public policy turn to for advice on therapy and research questions about brain diseases. I want to thank Alan Gelenberg who was the initial co-chair of this working group. We have now formed a standing liaison committee to address these issues as they arise. As the experts in the field we have a responsibility to our patients and society to weigh in on these important issues. Please contact our colleagues at Parthenon Management Group if you have an interest in this or any other ASCP activities or committees.

I hope you have a wonderful time learning, presenting, and seeing old and new friends at our annual meeting.

Mark H. Rapaport, M.D.
President
American Society of Clinical Psychopharmacology
Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2017 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

• 2017 Program Highlights
  o Monday, May 29th
    ▪ Latin American Symposium
  o Tuesday, May 30th
    ▪ Conference Opening
    ▪ Early Career Luncheon (RSVP Only)
    ▪ NIH Diversity Supplement Session
    ▪ Pharma Pipeline: 12 presentations of Phase 1 and Phase 2 developments
    ▪ Individual Research Reports
  o Wednesday, May 31st
    ▪ 18th Annual Fun Run/Walk
    ▪ Regulatory Plenary
    ▪ ASCP Lifetime Awardee Talk
    ▪ Poster Session I
    ▪ FDA 101 Session
    ▪ ASCP Reception
  o Thursday, June 1st
    ▪ Keynote Plenary Session: Serving the Needs of the Diverse Population
    ▪ Federal Agency Directors Plenary
    ▪ Poster Session II
    ▪ Clinical Updates in Psychopharmacology
  o Friday, June 2nd
    ▪ Regulatory Wrap-Up Plenary with FDA and EMA regulators
  o Throughout the meeting
    ▪ NIH, NIDA, and FDA panels
  o The New Investigator Program
    ▪ A closed workshop for 20 New Investigators and informal breakfast sessions.
  o Workshops: 2 hour intensive interactive sessions focused on problems and solutions
    ▪ Wednesday and Thursday Afternoons
  o “Clinical Track” – sessions focused on topics of immediate clinical relevance

• Organization
  o The meeting is sponsored by the American Society for Clinical Psychopharmacology (ASCP).
  o The Steering Committee organizes the meeting.
  o The Program Committee evaluates submitted proposals and develops program innovations.
  o Federal agency collaborations:
    ▪ CSR - Center for Scientific Review
    ▪ DoD - Department of Defense
    ▪ NIAAA - National Institute on Alcohol Abuse and Alcoholism
    ▪ NIDA - National Institute of Drug Abuse
    ▪ NIMH - National Institute of Mental Health
    ▪ NINDS - National Institute of Neurological Disorders and Stroke
    ▪ PCORI - Patient-Center Outcomes Research Institute
  o Regulatory agency collaborations:
    ▪ Food and Drug Administration (FDA)
    ▪ Center for Drug Evaluation and Research (CDER)
    ▪ European Medicines Agency (EMA)
    ▪ Italian Medicines Agency (AIFA)
  o Parthenon Management Group organizes the ASCP Annual Meeting.

• And remember
  o The Fun Run/Walk is Wednesday, May 31st at 6:30 a.m. All are welcome to join!
  o The ASCP Reception is Wednesday, May 31st from 6:45 p.m. – 7:45 p.m.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

Marlene Freeman, M.D.
Steering Committee Co-chair

John Newcomer, M.D.
Steering Committee Co-chair

Alan Gelenberg, M.D.
Program Committee Co-chair

Holly A. Swartz, M.D.
Program Committee Co-chair
| Award Winners and Featured Speakers | 5 |
| Acknowledgements                     | 17 |
| Meeting Announcements                | 23 |
| Monday, May 29, 2017                  | 27 |
| Tuesday, May 30, 2017                 | 33 |
| Wednesday, May 31, 2017               | 49 |
| Thursday, June 1, 2017                | 61 |
| Friday, June 2, 2017                  | 69 |
| Poster Session I                     | 75 |
| Poster Session II                    | 86 |
| Author Index                         | 97 |

DISCLOSURES FOR ALL ASCP PRESENTERS CAN BE VIEWED AT WWW.ASCPMEETING.ORG
Recipient of the Donald Klein Lifetime Achievement Award

David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

David J. Kupfer, M.D., is currently Distinguished Emeritus Professor of Psychiatry at the University of Pittsburgh School of Medicine. Between 1983 and 2009, Dr. Kupfer served as Chair of the Department of Psychiatry there and as Director of Research at Western Psychiatric Institute and Clinic. During that time, he facilitated the coordination and expansion of research among the department’s more than 200 faculty members. Under his direction, WPIC became one of the nation’s preeminent university-based psychiatric research centers, as evidenced by the quality and number of peer-review publications, as well as the amount of federal funding for mental health research. A prolific writer, Dr. Kupfer has authored or co-authored a combination of more than 1,120 articles, books, and book chapters. Dr. Kupfer’s own research has focused primarily on long-term treatment strategies for recurrent mood disorders, the pathogenesis of depression, and the relationship between biomarkers and depression. In 1990, he was elected to the National Academy of Medicine (formerly the Institute of Medicine).

Dr. Kupfer has served as President of the Society of Biological Psychiatry and the American College of Neuropsychopharmacology and was the Founding President of the International Society of Bipolar Disorders. Dr. Kupfer chaired the American Psychiatric Association Task Force for DSM-5. His proudest accomplishment, however, is the number of individuals he has mentored who have, in turn, become leaders in the fields of neuroscience and psychopharmacology.
Recipients of the Paul Wender Best Paper in the Journal of Clinical Psychiatry Award

Emil F. Coccaro, M.D.
Pritzker School of Medicine, University of Chicago

Nominated for: *Toxoplasma gondii* Infection: Relationship With Aggression in Psychiatric Subjects

Emil F. Coccaro, M.D.; Royce Lee, M.D.; Maureen W. Groer, Ph.D.; Adem Can, Ph.D.; Mary Coussons-Read, Ph.D.; and Teodor T. Postolache, M.D.

Dr. Emil F. Coccaro is currently the Ellen C. Manning Professor in the Department of Psychiatry & Behavioral Neuroscience at the Pritzker School of Medicine, University of Chicago. He received his undergraduate B.S. degree in Biology from Fordham University, where he graduated Magna Cum Laude in Cursu Honoram in 1975. Dr. Coccaro continued his studies at the New York University School of Medicine, completing his M.D. degree in 1979. After a medical internship at the University of Cincinnati Medical Center and a psychiatric residency at the Mount Sinai Medical Center in New York City, Dr. Coccaro joined the faculty of the Department of Psychiatry at the Mount Sinai School of Medicine in 1983. In 1989, Dr. Coccaro moved to Philadelphia to found and direct the Clinical Neuroscience Research Unit at the MCP Hahnemann School of Medicine. Dr. Coccaro moved to the Pritzker School of Medicine at the University of Chicago as the Director of the Clinical Neuroscience & Psychopharmacology Research Unit in September 1999. In 2004, he became Chairman of the Department and continued in that position through 2016. Dr. Coccaro is a Distinguished Fellow of the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP).

Dr. Coccaro’s work involves neurobiologic and treatment studies of impulsive aggressive behavior in humans. This work led to his authorship of the DSM-5 Criteria for Intermittent Explosive Disorder (IED). He is the recipient of various awards, including the A.E. Bennett Award for Outstanding Research and the National Alliance for the Mentally Ill’s Exemplary Psychiatrist Award. He serves on the editorial boards of several journals, among them the *Journal of Psychiatric Research*, *Journal of Personality Disorders*, and *Aggression and Violent Behavior*. In addition, he is the Editor of *Behavioral Neuroscience Reports*, and has been the Impulse Control and Personality Disorders Section Editor for *Current Psychiatry Reports*. Dr. Coccaro has been the recipient of a number of research grants from the National Institute of Mental Health, the American Foundation for Suicide Prevention, the Borderline Personality Disorder Research Foundation, and the Harry Frank Guggenheim Foundation. Dr. Coccaro is the author of more than 200 peer-reviewed journal articles, as well as more than 40 book chapters. He has edited three books, including *Aggression: Psychiatric Assessment and Treatment*, published by Marcel Dekker. He lectures widely on topics such as mood and personality disorders and the neuroscience, neuropsychopharmacology, genetics, and treatment of impulsive aggressive behavior.
Award Winners

New Investigator Awardees

Sofia Bouhlal, Ph.D.
National Institute on Alcohol Abuse and Alcoholism and Intramural Research Program, National Institute on Drug Abuse

Mehmet Burcu, Ph.D., M.S.
University of Maryland Baltimore

Shanna L. Burke, Ph.D., MSW, LCSW
Florida International University

Marco Antonio Knob Caldieraro, M.D., Ph.D.
Massachusetts General Hospital & Harvard Medical School

Simmie Foster, M.D., Ph.D.
Massachusetts General Hospital & Harvard Medical School

Srinath Gopinath, M.D.
SUNY Health Science Center at Brooklyn

Laura M. Hack, M.D., Ph.D.
Emory University School of Medicine

Ayana Jordan, M.D., Ph.D.
Yale University School of Medicine

Bashkim Kadriu, M.D.
National Institute of Mental Health

Bhanu Prakash Kolla, M.D.
Mayo Clinic

Emily Olfson, M.D., Ph.D.
Child Study Center, Yale School of Medicine

Laura Politte, M.D.
University of North Carolina at Chapel Hill

Rajiv Radhakrishnan, M.D.
Yale School of Medicine

Jose M. Rubio, M.D.
The Zucker Hillside Hospital

Dongju Seo, Ph.D.
Yale University School of Medicine

Anup Sharma, M.D., Ph.D.
University of Pennsylvania

Deena Walker, Ph.D.
Icahn School of Medicine at Mount Sinai

Kristen Ward, Pharm.D.
University of Michigan

Samuel Wilkinson, M.D.
Yale School of Medicine

Jessica Wojtalik, MSW
University of Pittsburgh School of Social Work

2016 ASCP Research Grant Awardee

Virginie-Anne Chouinard, M.D.
Harvard Medical School, McLean Hospital
Nominated for: Glucose Metabolism and Brain Bioenergetics Measured by 31P Magnetic Resonance Spectroscopy in Unaffected Siblings of Patients With Psychotic Disorders
See Dr. Chouinard’s poster on Thursday, June 1, 2017 at Poster #50.
Regulatory Plenary
Wednesday, May 31st from 8:30 a.m. – 10:00 a.m.

Tiffany Farchione, M.D.
US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh’s Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center, and was on the faculty of the University of Pittsburgh.

As the Deputy Director in the Division of Psychiatry Products at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.

Islam Younis, Ph.D.
US Food and Drug Administration

Dr. Younis holds a B.Sc. in Pharmacy from An-Najah National University, Palestine and M.Sc. and Ph.D. degrees in Pharmaceutical Sciences from West Virginia University. Islam has completed additional training leading to graduate certificates in Public Health, Drug Development and Regulatory Sciences, and Pharmacoepidemiology from Georgetown University, University of California at San Francisco, and University of Pennsylvania, respectively. He joined FDA in 2008 and worked as a clinical pharmacology reviewer on the CardioRenal and Psychiatry teams. In 2012, Islam was selected as the team leader for the Antiviral Team. In 2016, Islam was selected to also lead the Clinical Pharmacology team responsible for review of application submitted under the animal rule and as an associate member in the Office of Clinical Pharmacology OCP Guidance and Policy Team. Islam has been active in regulatory science and mentorship of Pharm D students and fellows. Islam has published 17 peer reviewed papers, 19 conference abstracts, and two book chapters and presented in national meetings. He is also leading multiple regulatory research projects focusing on leveraging prior knowledge toward optimizing clinical trials and improving drug development efficiency in schizophrenia and specific populations (mainly hepatic and renal impairment). Islam served as a member on several FDA guidance working groups including exposure-response, HIV, HCV, and HBV guidance working groups.
Featured Speakers

Luca Pani, M.D.
European Medicines Agency

Luca Pani, M.D., specialized in Psychiatry, is an Expert in Pharmacology and Molecular Biology, and a Fellow of the National Research Council of Italy who has served as Director General of the Italian Medicines Agency (AIFA) from 2011 to 2016, with CEO roles of both Regulator and Negotiator / Payer.

He is currently Italian Alternate Member of the Committee for Human Medicine Products (CHMP); Full Member of the Scientific Advice Working Party (SAWP); participant of the Working Party on Central Nervous System (WPCNS) and has been the Chair of both the European Union Management Board Telematic Committee (EUMBTC) and the EU Network Pharmacovigilance Oversight Group for the European Medicines Agency (EMA) in London (UK) from 2013 to 2016.

Luca Pani is the author of over one hundred and fifty scientific publications, editor and author of several volumes and also a writer of successful leisure literature. He has attended over 1,000 conferences, seminars, workshops and national and international roundtables as an invited speaker. He is currently associated with the Faculty of the Department of Psychiatry and Behavioural Sciences at the University of Miami School of Medicine, in USA.

Valentina Mantua, M.D., Ph.D.
Italian Medicines Agency (AIFA)

Valentina Mantua is a medical doctor and a psychiatrist with an extensive clinical experience in the field of psychosis and affective disorders both at the Maudsley NHS Trust in London and University Hospital in Pisa, Italy, where she also obtained a Ph.D. in Neurobiology of Affective Disorders.

She joined the regulatory world in 2012 as expert CNS assessor at the Italian Medicines Agency (AIFA) and she is currently Italian Alternate Member of the Scientific Advice Working Party (SAWP) and Full Member of the Central Nervous System Working Party on (CNSWP) at the European Medicines Agency (EMA). She is also the Italian representative at the EU-Innovation Network, supporting innovation in drug development both at a national and European level.
Featured Speakers

Keynote Plenary: Serving the Needs of the Diverse Population
Thursday, June 1st from 8:15 a.m. - 9:45 a.m.

Roberto Lewis-Fernández, M.D.
Columbia University & New York State Psychiatric Institute

Roberto Lewis-Fernández, M.D. is Professor of Clinical Psychiatry at Columbia University and Director of the New York State Center of Excellence for Cultural Competence and the Hispanic Treatment Program, and Co-Director of the Anxiety Disorders Clinic, at New York State Psychiatric Institute. His research focuses on developing culturally valid interventions and instruments to enhance patient engagement, reduce misdiagnosis, and help overcome disparities in the care of underserved cultural groups, especially Latinos. He is Chair of the Cultural Committee of the Group for the Advancement of Psychiatry, President of the Society for the Study of Psychiatry and Culture, President-elect of the World Association of Cultural Psychiatry, and Past President of the American Society of Hispanic Psychiatry. He was a member of the NIMH National Advisory Mental Health Council and Chair of the Cross-Cultural Issues Subgroup of DSM-5. Currently, he is Co-chair of the ICD-11 Working Group on Culture-Related Issues and a member of the Working Group on Somatic Distress and Dissociative Disorders.

Michael T. Compton, M.D., M.P.H.
Columbia University, College of Physicians and Surgeons

Michael T. Compton, M.D., M.P.H., is Professor of Psychiatry at the Columbia University College of Physicians & Surgeons. He is also Medical Director for Adult Services for the New York State Office of Mental Health, the State’s public mental health system. OMH regulates, certifies, and oversees more than 4,500 mental health programs, and also directly provides State-operated mental health services at 17 adult State hospitals and more than 60 adult outpatient clinics.

After completing medical school at the University of Virginia in 1997, Dr. Compton trained in general psychiatry, preventive medicine, public health, and community psychiatry, all at Emory University in Atlanta, Georgia. He served on faculty as an Assistant Professor, and then tenured Associate Professor, at Emory from 2003 to 2010. He then served as Professor and Director of Research Initiatives in the Department of Psychiatry and Behavioral Sciences at The George Washington University School of Medicine and Health Sciences in downtown D.C., from 2011 to 2013. Upon relocating to New York, he was Chairman of Psychiatry at Lenox Hill Hospital in the Upper East Side and Professor of Psychiatry at Hofstra Northwell School of Medicine for three years.
Dr. Compton has had continuous NIMH research funding for more than 15 years, conducting research on first-episode psychosis, the Crisis Intervention Team (CIT) model of collaboration between law enforcement and mental health, linguistic abnormalities in persons with schizophrenia, and the effectiveness of a new form of recovery-oriented community navigation for persons with serious mental illnesses and repeated hospitalizations. His research has led to more than 200 publications. He is also very interested in incorporating public health and prevention into psychiatry, one means of which is by addressing the social determinants of health. Dr. Compton teaches in a wide array of settings and serves on a number of institutional, regional, and national committees. He is a Fellow of the American College of Preventive Medicine and a Distinguished Fellow of the American Psychiatric Association. Recent honors include being a Visiting Professor at the University of Perugia, Italy last year; Honorary Professor at the Mexican Psychiatric Institute last year; and the 2016 Luke and Grace Kim Visiting Professor in Cultural Psychiatry at University of California – Davis earlier this year. His edited books include, among others, the Clinical Manual of Prevention in Mental Health (2009); The Social Determinants of Mental Health (2015), and Marijuana and Mental Health (2016).

Andrew Nierenberg, M.D.
Massachusetts General Hospital & Harvard Medical School

Dr. Andrew Nierenberg is a graduate of the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. He completed his residency in psychiatry at New York University/Bellevue Hospital. He next studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar and then joined the faculty at Harvard Medical School at McLean Hospital in Belmont, Massachusetts. He then joined the Department of Psychiatry at Massachusetts General Hospital in Boston, where he holds his current positions.

Dr. Nierenberg has published over 440 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. He was awarded the Gerald L. Klerman Young and Senior Investigator Awards by the Depression and Bipolar Support Alliance, the Brain and Behavior Research Foundation Colvin Prize, and was listed in 2014 and 2015 as among the world’s most influential scientific minds by Thomson Reuters for having the top 1% of citations in psychiatry.

He is the incumbent holder of the Thomas P. Hackett, M.D. Endowed Chair in Psychiatry at MGH, and Director of the Dauten Family Center for Bipolar Treatment Innovation as well as professor of psychiatry at Harvard Medical School.
Featured Speakers

Federal Agency Directors Plenary
Thursday, June 1st from 10:00 a.m. – 12:30 p.m.

Raye Litten, Ph.D.
National Institute on Alcohol Abuse and Alcoholism

Dr. Litten is the Acting Director, Division of Medications Development at National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH. He manages the NIAAA medications development program to treat Alcohol Use Disorder (AUD). Dr. Litten oversees the development of efficacious medications by translating neuroscience discoveries into lead compounds and advancing them through drug development pipeline. He oversees two recent NIAAA initiatives, the NCIG clinical trials network and the human laboratory program for testing candidate compounds. He is a member of the Steering Committee of the American Society of Clinical Psychopharmacology and the Alcohol Clinical Trials Initiative (ACTIVE) group. He is also a member of the Steering Committee of Department of Defense Alcohol and Substance Disorders Research Program.

Dr. Litten received his Ph.D. from the Department of Physiology, Virginia Commonwealth University and completed his post-doc in the Department of Physiology and Biophysics, University of Vermont. He arrived at NIAAA in 1989 and has served as Chief of the Treatment Research Branch and later as Associate Director in the Division of Treatment and Recovery Research.
Amir Tamiz, Ph.D.
National Institute of Neurological Disorders and Stroke

Dr. Tamiz is the Director of the Division of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS). Prior to that he was a Program Director overseeing the NIH Blueprint Neurotherapeutics Network (BPN) and Innovation Grants to Nurture Initial Translational Efforts (IGNITE). Blueprint Neurotherapeutics Network is a collaborative effort among 15 of the agency's institutes and centers, leveraging their resources to offer neuroscience researchers grant funding for drug discovery and development activities to confront major, cross-cutting challenges in neuroscience. The program was established as a pipeline between academic and industry drug development research and offers neuroscience researchers a “virtual pharma” to develop promising hit compounds from chemical optimization through Phase I clinical testing. Principal Investigators receive grant funding and in kind discovery and development resources such as medicinal chemistry, API synthesis and manufacture, formulation and drug product manufacture, IND enabling studies, and clinical trial capabilities. Launched in December 2014, IGNITE program is intended to create a more contiguous source of support from discovery to preclinical development. The first two programs include: 1) Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (PAR-15-070) and 2) Pharmacodynamics and in vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (PAR-15-071). Prior to joining NIH in 2012, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer), and Alba Therapeutics. Dr. Tamiz received his Ph.D. at University of Oregon and conducted postdoctoral research at the Department of Neuroscience at Georgetown University Medical Center.
Josh Gordon, M.D., Ph.D.
National Institute of Mental Health

Dr. Gordon received his M.D./Ph.D. at the University of California, San Francisco and completed his Psychiatry residency at Columbia University. He joined the Columbia faculty in 2004. He became the Director of the National Institute of Mental Health in September 2016.

Dr. Gordon’s research focuses on the analysis of neural activity in mice carrying mutations of relevance to psychiatric disease. He employs a range of systems neuroscience techniques, including in vivo anesthetized and awake behaving recordings and optogenetics, the use of light to control neural activity. His work has direct relevance to schizophrenia, anxiety disorders, and depression.

Dr. Gordon has received several prestigious awards, including the The Brain and Behavior Research Foundation – NARSAD Young Investigator Award, the Rising Star Award from the International Mental Health Research Organization, the A.E. Bennett Award from the Society of Biological Psychiatry, and the Daniel H. Efron Award from the American College of Neuropsychopharmacology.

Kevin Walton, Ph.D.
National Institute on Drug Abuse

Dr. Kevin Walton is the Chief of the Clinical Research Grants Branch in the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH). His branch is responsible for leading the grant-funded clinical research exploring new medication, behavioral, and device development for the treatment of substance use disorders. After a position as an Assistant Professor at the University of Michigan, Dr. Walton spent 15 years in neuroscience drug discovery in the biotech and pharmaceutical industries where he worked on developing novel medications for both neurological and psychiatric disorders. He has been at NIH since 2010 and joined NIDA in 2013. Dr. Walton received his Ph.D. in Pharmacology at the Johns Hopkins University School of Medicine.
Featured Speakers

Richard K. Nakamura, Ph.D.
Center for Scientific Review

Dr. Richard K. Nakamura is the Director of the Center for Scientific Review at National Institutes of Health. In that capacity, he leads the review of grant applications of the National Institutes of Health. Dr. Nakamura received his Bachelor of Arts in Psychology from Earlham College and his Ph.D. in Psychology from State University of New York (Stony Brook, NY). He was with the National Institute of Mental Health from 1976 to 2011. In 2001, he received the NIH-Asian/Pacific American Organization (APAO) Outstanding Achievement Award for Administrative Work. In 2002, Dr. Nakamura was elected by the American Association for the Advancement of Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded the Presidential Rank Award for outstanding leadership. In 2004 and 2005 respectively, he received leadership awards from the Federation of Behavioral Psychological and Cognitive Sciences, and from the International Society for Behavioral Neuroscience. In 2009, he was awarded the NIH Director's Award for Outstanding Administration.

Grayson Norquist, M.D., MSPH
Patient-Centered Outcomes Research Institute

Grayson Norquist, M.D., MSPH, is Vice-Chair, Emory University Department of Psychiatry and Behavioral Sciences, and Chief of Psychiatry Service at Grady Health System in Atlanta. Before joining Emory, he was Professor and Chair of the Department of Psychiatry and Human Behavior, at the University of Mississippi School of Medicine. He served in a number of leadership positions at the National Institute of Mental Health (NIMH), including director of the Division of Services and Intervention Research, a division responsible for clinical, prevention, and services research at NIMH. Norquist has been a member of several journal editorial boards, including Psychiatric Services, Archives of General Psychiatry and Journal of Mental Health Policy and Economics, and received various national government and public awards, including the NIH Director's Award, the NIH Special Service Award, and the National Alliance for the Mentally Ill Exemplary Psychiatrist Award. He received a BA from the University of Mississippi, a MPH from the UCLA School of Public Health, and a M.D. from the University of Mississippi Medical Center. His research has focused on improving mental health services for underserved populations and development of quality measures.
Colonel Dennis McGurk, Ph.D.
Military Operational Medicine Research Program

COL Dennis McGurk entered the military in 1990 as an Infantryman in the Army Reserve. He was commissioned as a Medical Service Corps Officer in 1994. COL McGurk earned his Ph.D. in Experimental Psychology from Texas Tech University in 2002. He has served as a Platoon Leader, Operations Officer, Company Commander, Research Branch Chief, and Detachment Commander. During his 22+ years of military service, COL McGurk has deployed to Haiti, Kosovo, Iraq and Afghanistan. He has published in peer-reviewed journals, was the lead author on two book chapters, has presented to numerous scientific and military conferences and has briefed many senior military leaders to include the Under Secretary of Defense for Personnel and Readiness, the Secretary of the Army and the Secretary of the Navy.

Regulatory Wrap-Up
Friday, June 2nd from 10:15 a.m. – 11:45 a.m.

Tiffany Farchione, M.D.
US Food and Drug Administration
See previous bio

Islam Younis, Ph.D.
US Food and Drug Administration
See previous bio

Luca Pani, M.D.
European Medicines Agency
See previous bio

Valentina Mantua, M.D., Ph.D.
Italian Medicines Agency (AIFA)
See previous bio
Acknowledgements

Steering Committee Chairs

Marlene Freeman, M.D.  John Newcomer, M.D.

Program Committee Chairs

Alan Gelenberg, M.D.  Holly Swartz, M.D.

New Investigator Award Program Chairs

Mark H. Rapaport, M.D.  Christopher Sarampote, Ph.D.
**Steering Committee Members**

- Ross Baker, M.D.
  Otsuka Pharmaceuticals

- Lori Davis, M.D.
  Tuscaloosa VA Medical Center

- Elliot Ehrich, M.D.
  Alkermes Pharmaceuticals

- Tiffany Farchione, M.D.
  US Food and Drug Administration

- Alan Gelenberg, M.D.
  *Journal of Clinical Psychiatry*

- David J. Kupfer, M.D.
  University of Pittsburgh School of Medicine

- Raye Litten, Ph.D.
  National Institute of Alcohol Abuse and Alcoholism

- Antony Loebel, M.D.
  Sunovion Pharmaceuticals

- Stephen Marder, M.D.
  Semel Institute, University of California, Los Angeles

- Stephanie O’Malley, Ph.D.
  Yale University School of Medicine

- Joseph Palumbo, M.D.
  Mitsubishi Tanabe Pharma Development America

- Luca Pani, M.D.
  European Medicines Agency

- Mark H. Rapaport, M.D.
  Emory University School of Medicine

- Holly Swartz, M.D.
  University of Pittsburgh School of Medicine

- Madhukar Trivedi, M.D.
  University of Texas Southwestern Medical Center

- Benedetto Vitiello, M.D.
  University of Turin

**New Investigator Alumni**  *Representing ASCP CME Committee*
Acknowledgements

Program Committee Members

Scott Aaronson, M.D.
Sheppard Pratt Health Systems

Mohammed Ahmed, M.D.
University of California, San Diego

* Isabelle Bauer, Ph.D.
University of Texas at Houston

* Ram Bishnoi, M.D.
University of Texas Health Center, San Antonio

Leslie Citrome, M.D., M.P.H.
New York Medical College

* Crystal Clark, M.D.
Northwestern University

* Anita Clayton, M.D.
University of Virginia

Lawrence Cohen, Pharm.D.
University of North Texas Health Science Center

* Christoph U. Correll, M.D.
The Zucker Hillside Hospital

Lynn Crismon, Pharm.D.
The University of Texas at Austin

* Tiffany Farchione, M.D.
US Food and Drug Administration

Maurizio Fava, M.D.
Massachusetts General Hospital

* Bradley Gaynes, M.D.*
University of North Carolina

Ahmad Hameed, M.D.
Pennsylvania State College of Medicine

Usman Hameed, M.D.
Penn State Hershey Medical Center

* Ebrahim Haroon, M.D.
Emory University School of Medicine

★ New Investigator Alumni ★ Representing ASCP CME Committee
Acknowledgements

Program Committee Members (continued)

Michael Henry, M.D.  
Massachusetts General Hospital

Richard Keefe, Ph.D.  
Duke University Medical Center

Susan Kornstein, M.D.  
Virginia Commonwealth University

Maria Lisotto, M.D.  
Massachusetts General Hospital/McLean Hospital

Stephen Marder, M.D.  
Semel Institute, University of California, Los Angeles

Tim Mariano, M.D., Ph.D.  
Harvard Medical School

Barbara Milrod, M.D.  
Weill Cornell University

Francisco Moreno, M.D.  
University of Arizona

Craig Nelson, M.D.*  
University of California, San Francisco

Katharine Phillips, M.D.  
Rhode Island Hospital/Brown University

Bruce Saltz, M.D., P.A.  
Mental Health Advocates, Inc.

Erika Saunders, M.D.  
Pennsylvania State College of Medicine

Richard Shelton, M.D.  
University of Alabama at Birmingham

Jair Soares, M.D.  
University of Texas School of Medicine at Houston

Mark Stein, M.D.  
University of Washington

Antonio Teixeira, M.D.  
University of Texas Health Science Center at Houston

★ New Investigator Alumni  *Representing ASCP CME Committee
Program Committee Members (continued)

Benedetto Vitiello, M.D.
National Institute of Mental Health

★ Carlos A. Zarate, M.D.
National Institute of Mental Health

★ Jianping Zhang, M.D., Ph.D.
The Zucker Hillside Hospital

New Investigator Award Program Committee

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

★ Lori Davis, M.D.
Tuscaloosa VA Medical Center

★ Tiffany Farchione, M.D.
US Food and Drug Administration

Bruce Kinon, M.D.
Lundbeck

Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Lynn Morin, M.A.
National Institute on Alcohol Abuse and Alcoholism

★ Katharine Phillips, M.D.
Rhode Island Hospital / Brown University

A. John Rush, M.D.
National University of Singapore

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

★ Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine

★ New Investigator Alumni ★ Representing ASCP CME Committee
Acknowledgements

ASCP Officers and Board

Mark H. Rapaport, M.D. – ASCP President
Emory University School of Medicine

Maurizio Fava, M.D. – ASCP Past-President
Massachusetts General Hospital

Michael Thase, M.D. – ASCP Treasurer & ASCP President-elect
University of Pennsylvania

John Newcomer, M.D. – ASCP Treasurer-elect
Charles E. Schmidt College of Medicine, Florida Atlantic University

Joseph Calabrese, M.D.
University Hospitals Cleveland Medical Center

Leslie Citrome, M.D., M.P.H.
New York Medical College

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

★ Kristina Deligiannidis, M.D.
The Zucker Hillside Hospital; Feinstein Institute for Medical Research; Hofstra Northwell School of Medicine

Marlene Freeman, M.D.*
Massachusetts General Hospital

Alan Gelenberg, M.D.
Journal of Clinical Psychiatry

Joseph Goldberg, M.D.*
Icahn School of Medicine at Mount Sinai

John Kane, M.D.*
The Zucker Hillside Hospital

Arifulla Khan, M.D.
Northwest Clinical Research Center

★ Katharine Phillips, M.D.
Rhode Island Hospital / Brown University

★ Madhukar Trivedi, M.D.
UT Southwestern Medical Center

Sidney Zisook, M.D.
University of California, San Diego

Stephen Marder, M.D.
Semel Institute, University of California, Los Angeles, Board Member-elect

Trisha Suppes, M.D.*
Stanford University, Board Member-elect

★ New Investigator Alumni  *Representing ASCP CME Committee
Meeting Services

Registration Desk Hours:
Monday 10:00 a.m. – 5:00 p.m.
Tuesday 7:30 a.m. – 6:00 p.m.
Wednesday 7:30 a.m. – 7:00 p.m.
Thursday 7:30 a.m. – 6:00 p.m.
Friday 7:30 a.m. – 12:00 p.m.
*The registration/meeting information desk is located in the Rotunda East on the Second Level.

The ASCP Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Sundial meeting room, on the Third Level.
Monday 11:00 a.m. – 5:00 p.m.
Tuesday - Thursday 7:30 a.m. – 6:30 p.m.
Friday 7:30 a.m. – 10:30 a.m.

ASCP Wi-Fi
Network: ascp2017
Access PIN: ascp2017

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Discounts – All ASCP Annual Meeting attendees who booked their room at the Loews Miami Beach through the ASCP meeting website will have the following resort amenities complimentary:
- Internet in the guest rooms
- Fitness Center admittance
- Access to Newspapers with Loews Mobile App

ASCP Membership - If you would like to join ASCP, you can log onto our website at https://www.ascpp.org/ and register online. Membership applications are available at the ASCP membership booth, located next to the meeting registration desk in the Rotunda East on the Second Level. You may also contact the ASCP office at 615-649-3085 to request one.

ASCP Fellow Membership
If you have been a member of ASCP for 10+ consecutive years and attended 5 or more meetings, you may be eligible for Fellowship Membership. Contact ASCP's Executive Office, info@ascpp.org, for more information or to confirm your status.
Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMobile.org.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. Self-Assessment maintenance of certification credits are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the conference at www.ASCPMobile.org. Surveys for continuing education credit must be submitted no later than June 30, 2017. There is a $40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE ANNUAL MEETING AND HAS APPROVED THIS PROGRAM AS PART OF A COMPREHENSIVE SELF-ASSESSMENT PROGRAM, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF MAINTENANCE OF CERTIFICATION.

Satisfactory completion
Participants must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians/Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the American Society of Clinical Psychopharmacology (ASCP). Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement – Amedco designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 26.0 contact hours. Note: The Unique Activity Numbers are pending and will be posted online at a later date.

In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.

Psychologists

This course is co-sponsored by Amedco and American Society of Clinical Psychopharmacology (ASCP). Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 26.0 hours. Partial credit will not be awarded.

All participants who request continuing education credits by June 30, 2017, should expect to receive their statement of credits via email in July.

The Meeting Evaluation Survey will be available at www.ASCPMeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. There is a $40.00 administrative fee for CME/CE applications. Your candid input on the 2017 meeting is appreciated as we strive to improve the meeting each year.
ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

- ACADIA Pharmaceuticals, Inc.
- Alkermes, Inc.
- Avanir Pharmaceuticals
- Neurocrine
- Sunovion Pharmaceuticals, Inc.

2018 ASCP Annual Meeting – Save the Date

The 2018 ASCP Annual Meeting will take place May 28 – June 1, 2018 at the Loews Miami Beach Hotel in Miami, Florida. Details regarding abstract submissions for the 2018 Meeting will be released in September 2017.
### AT-A-GLANCE

**Monday, May 29, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 4:15 p.m.</td>
<td>NIA Workshop (Invitation Only)</td>
<td>Cowrie 2</td>
</tr>
<tr>
<td>10:00 a.m. - 5:00 p.m.</td>
<td>Registration</td>
<td>Rotunda East</td>
</tr>
<tr>
<td>11:00 a.m. - 5:00 p.m.</td>
<td>Speaker Ready Room</td>
<td>Sundial</td>
</tr>
<tr>
<td>12:00 p.m. - 1:50 p.m.</td>
<td>Latin America Symposium*</td>
<td>Poinciana 1-2</td>
</tr>
<tr>
<td>1:50 p.m. - 2:00 p.m.</td>
<td>Break</td>
<td>Poinciana 1-2</td>
</tr>
<tr>
<td>2:00 p.m. - 4:00 p.m.</td>
<td>Latin America Symposium*</td>
<td>Poinciana 1-2</td>
</tr>
</tbody>
</table>

*of special interest to clinicians
The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers’ assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions and orals during the Individual Research Reports on Tuesday, May 30, 2017. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an awards ceremony on Tuesday evening, May 30, 2017. This year marks the 25th year of the New Investigator program with 20 New Investigator awardees that are indicated with a ribbon in the poster section of this program; they will also be notated with a ribbon icon in the program book.

Faculty

Nina Schooler, Ph.D.
SUNY Downstate Medical Center
A. John Rush, M.D.
National University of Singapore
Holly Swartz, M.D.
University of Pittsburgh
Michael Davis, M.D., Ph.D.
US Food and Drug Administration

Bruce Kinon, M.D.
Lundbeck
Tiffany Farchione, M.D.
US Food and Drug Administration
Lynn Morin, M.A.
National Institute on Alcohol Abuse and Alcoholism
Kevin Walton, Ph.D.
National Institute on Drug Abuse
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:00 a.m. - 5:00 p.m. | Registration Open  
*of special interest to clinicians*  
*Rotunda East* |
| 11:00 a.m. - 5:00 p.m. | Speaker Ready Room  
*Sundial* |
| 12:00 p.m. - 1:50 p.m. | Latin America Symposium*  
*Poinciana 1-2* |

**Chair:** Francisco Moreno, University of Arizona

12:00 p.m. - 12:20 p.m.  
**Welcome and Introduction to the Latin American Symposium Speaker Introduction**

12:20 p.m. - 12:50 p.m.  
**Overcoming Latino Mental Health Disparities via Health Promotion**  
Daniel Jimenez, University of Miami

12:50 p.m. - 1:20 p.m.  
**Identifying Patients With Bipolar Disorders in Emergency Departments in Latin-American Countries: Comorbidity and Leading Symptoms**  
Ruby Castilla Puentes, Johnson and Johnson

1:20 p.m. - 1:50 p.m.  
**Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13) in OCD: Proof-of-Concept**  
Carolyn Rodriquez, Stanford University

1:50 p.m. - 2:00 p.m.  
**Break**  
*Poinciana 1-2*
Monday, May 29, 2017

2:00 p.m. - 4:00 p.m. Latin America Symposium*
   
   Chair: Francisco Moreno, University of Arizona

2:00 p.m. - 2:10 p.m. Welcome and Introduction

2:10 p.m. - 2:40 p.m. Atypical Antipsychotics in the Treatment of PTSD
   Gerardo Villarreal, University of New Mexico

2:40 p.m. - 3:10 p.m. PTSD and Gender Violence: Ecuador Experience
   Victoria Valdez, International Federation of Societies of Biological Psychiatry

3:10 p.m. - 3:40 p.m. Pharmacological Updates in Mood Disorders
   Rodrigo Machado-Vieira, UTHSC at Houston, School of Medicine

3:40 p.m. - 4:00 p.m. Closing: Wrap up and Final Remarks

*of special interest to clinicians
Tuesday, May 30, 2017

AT-A-GLANCE

Tuesday, May 30, 2017

7:30 a.m. - 6:00 p.m.  Registration
                      Rotunda East

7:30 a.m. - 6:30 p.m. Speaker Ready Room
                      Sundial

7:30 a.m. - 8:30 a.m. NIA Breakfast Roundtable (Invitation Only)
                      Neptune

7:30 a.m. - 9:00 a.m. Morning Break
                      Americana Foyer

8:30 a.m. - 9:00 a.m. Conference Opening
                      Salon 3

9:00 a.m. - 10:30 a.m. Panel Sessions

| The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses* | Implementing Measurement-Based Care in Clinical Practice* | Inflammation and Obesity in Depression: Neurobiological Mechanisms and Therapeutic Implications* | Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes* |
| Poinciana 1-2            | Poinciana 3-4                      | Salon 1                                                | Salon 2 |

10:30 a.m. - 10:45 a.m. Break
                      Americana Foyer

*of special interest to clinicians
10:45 a.m. - 12:15 p.m. **Panel Sessions**

<table>
<thead>
<tr>
<th>The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE)</th>
<th>Targeting Treatment Needs in Women’s Mental Health*</th>
<th>Model-Based Approaches to Assist Clinical Development of Psychiatric Products</th>
<th>Development of Antidepressants With Novel Mechanisms of Action*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poinciana 1-2</td>
<td>Poinciana 3-4</td>
<td>Salon 1</td>
<td>Salon 2</td>
</tr>
</tbody>
</table>

12:15 p.m. - 1:15 p.m. **Early Career Lunch (RSVP Only)**

Cowrie 1

1:15 p.m. - 1:45 p.m. **NIH Diversity Supplement Program***

Salon 1

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipelines**

Salon 3

4:00 p.m. - 4:15 p.m. **Break**

Americana Foyer

4:15 p.m. - 5:30 p.m. **Individual Research Reports**

<table>
<thead>
<tr>
<th>Understanding and Optimizing Treatments for Special Populations: Hypersomnia, Binge Eating Disorder, Pregnant Women With Depression, and Bipolar Depressive Episodes With Psychosis*</th>
<th>Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders*</th>
<th>Advances in Schizophrenia Treatment and Assessment*</th>
<th>Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poinciana 1-2</td>
<td>Poinciana 3-4</td>
<td>Salon 1</td>
<td>Salon 2</td>
</tr>
</tbody>
</table>

6:15 p.m. - 7:45 p.m. **New Investigator Awards Ceremony (Invitation Only)**

Cowrie 1-2

*of special interest to clinicians
**FULL SCHEDULE**

**Tuesday, May 30, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m. - 6:00 p.m.</td>
<td>Registration</td>
<td>Rotunda East</td>
</tr>
<tr>
<td>7:30 a.m. - 6:30 p.m.</td>
<td>Speaker Ready Room</td>
<td>Sundial</td>
</tr>
<tr>
<td>7:30 a.m. - 8:30 a.m.</td>
<td>NIA Breakfast Roundtable (Invitation Only)</td>
<td>Neptune</td>
</tr>
<tr>
<td>7:30 a.m. - 9:00 a.m.</td>
<td>Morning Break</td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>8:30 a.m. - 9:00 a.m.</td>
<td>Conference Opening</td>
<td>Salon 3</td>
</tr>
</tbody>
</table>

**Panel Sessions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. - 10:30 a.m.</td>
<td>The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses*</td>
<td>Poinciana 1-2</td>
</tr>
</tbody>
</table>

*Chair:* Maurizio Fava, Massachusetts General Hospital  
*Discussant:* Jonathan Alpert, Massachusetts General Hospital

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. - 9:10 a.m.</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>9:10 a.m. - 9:25 a.m.</td>
<td>Preclinical Evidence for Potential Therapeutic Effects of Opioid Modulators in Neuropsychiatric Conditions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simmie Foster, Massachusetts General Hospital &amp; Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td>9:25 a.m. - 9:40 a.m.</td>
<td>The Role of Buprenorphine/Samidorphan in the Treatment of Resistant Depression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elliot Ehrich, Alkermes, PLC</td>
<td></td>
</tr>
<tr>
<td>9:40 a.m. - 9:55 a.m.</td>
<td>A Clinical Development Program in Psychiatry for a Selective Kappa Antagonist</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ronald Marcus, Cerecor</td>
<td></td>
</tr>
</tbody>
</table>

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00 a.m. - 10:30 a.m. (continued) | The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses*  
*Poinciana 1-2* |
| 9:55 a.m. - 10:10 a.m. | Tramadol and Other Opioid Agents in Refractory OCD  
Paul Keck, Lindner Center of HOPE/University of Cincinnati |
| 10:10 a.m. - 10:30 a.m. | Discussion |
| 9:00 a.m. - 10:30 a.m. | Implementing Measurement-Based Care in Clinical Practice*  
*Poinciana 3-4* |

**Chair:** Erika Saunders, Penn State College of Medicine  
**Discussant:** Alan Gelenberg, *Journal of Clinical Psychiatry*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. - 9:10 a.m.</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 9:10 a.m. - 9:25 a.m. | Measurement-Based Care: A Platform for Personalized Clinical Decision-Making  
A. John Rush, National University of Singapore |
| 9:25 a.m. - 9:40 a.m. | Design and Implementation of the PCARES Program: Penn State Clinical Assessment and Rating Evaluation System  
Erika Saunders, Penn State College of Medicine |
| 9:40 a.m. - 9:55 a.m. | Penn State Clinical Assessment and Rating Evaluation System for Youth  
Daniel Waschbusch, Penn State Milton S. Hershey Medical Center |
| 9:55 a.m. - 10:10 a.m. | Mood Outcomes Program: National Network of Depression Centers  
David Katzelnick, Mayo Clinic |
| 10:10 a.m. - 10:30 a.m. | Discussion |
9:00 a.m. - 10:30 a.m.  Inflammation and Obesity in Depression: Neurobiological Mechanisms and Therapeutic Implications*

*of special interest to clinicians

**Salon 1**

**Chair:** Jennifer Felger, Emory University School of Medicine

**Co-Chair, Discussant:** Mark Rapaport, Emory University School of Medicine

9:00 a.m. - 9:10 a.m.  **Introduction**

9:10 a.m. - 9:30 a.m.  **Obesity as a Moderator of Response to Antidepressants**

Richard Shelton, University of Alabama at Birmingham

9:30 a.m. - 9:50 a.m.  **Inflammation Effects on Reward Circuitry and Motivation: Treatment Considerations for Depression**

Jennifer Felger, Emory University School of Medicine

9:50 a.m. - 10:10 a.m.  **Inflammatory Biomarkers as Viable Moderators for Treatment Selection - Results From the COMED Trial**

Madhukar Trivedi, UT Southwestern Medical Center

10:10 a.m. - 10:30 a.m.  **Discussion**

9:00 a.m. - 10:30 a.m.  Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*

**Salon 2**

**Chair:** Nina Schooler, SUNY Downstate Medical Center

**Co-Chair:** John Kane, The Zucker Hillside Hospital

**Discussant:** Dawn Velligan, University of Texas Health Science Center

9:00 a.m. - 9:10 a.m.  **Introduction**

9:10 a.m. - 9:30 a.m.  **Impact of Antipsychotic Medication Dose and Adherence on Improvement During Cognitive Remediation in Early Course Schizophrenia**

Shaun Eack, University of Pittsburgh

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00 a.m. - 10:30 a.m. (continued) | Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*  
**Salon 2** |
| 9:30 a.m. - 9:50 a.m. | Antipsychotic Medication Effects in the Context of Psychosocial Treatments after an Initial Episode of Schizophrenia  
Keith Nuechterlein, Semel Institute for Neuroscience & Human Behavior at UCLA |
| 9:50 a.m. - 10:10 a.m. | Psychopharmacological Treatment in the RAISE-ETP Study: A Manual and Computer Decision Support System Based Intervention Within a Comprehensive First Episode Specialty Care Program  
Delbert Robinson, Hofstra NS-LIJ School of Medicine |
| 10:10 a.m. - 10:30 a.m. | Discussion |
| 10:30 a.m. - 10:45 a.m. | Break  
**Americana Foyer** |

**Panel Sessions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:45 a.m. - 12:15 p.m. | The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE)  
**Poinciana 1-2** |
| Chair: | Stephanie O’Malley, Yale University School of Medicine |
| Co-Chair: | Daniel Falk, NIAAA/NIH |
| Discussant: | Bernard Silverman, Alkermes, Inc. |
| 10:45 a.m. - 10:55 a.m. | Introduction |
| 10:55 a.m. - 11:15 a.m. | Patient-Reported Outcomes to Capture the Patient Voice in Drug Development: A Regulatory Perspective  
Elektra Papadopoulos, US Food and Drug Administration |

*of special interest to clinicians*
10:45 a.m. - 12:15 p.m. The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE)  
*of special interest to clinicians*

Poinciana 1-2

11:15 a.m. - 11:35 a.m. Alcohol Clinical Trials Initiative (ACTIVE) Validation of a Potential Patient-Reported Outcome Measure of Alcohol-Related Consequences (the IMBIBE) and Its Use as an Endpoint in Alcohol Pharmacotherapy Trials 
Daniel Falk, NIAAA/NIH

11:35 a.m. - 11:55 a.m. The Patient-Reported Outcomes Measurement Information System (PROMIS) Program: An NIH-Funded Effort to Develop a Psychometrically-Sound Pro Item Bank: Tobacco and Alcohol Banks 
Maria Edelen, RAND Corporation

11:55 a.m. - 12:15 p.m. Discussion

10:45 a.m. - 12:15 p.m. Targeting Treatment Needs in Women’s Mental Health*  
Poinciana 3-4

Chair: Marlene Freeman, Massachusetts General Hospital  
Discussant: Lee Cohen, Massachusetts General Hospital

10:45 a.m. - 10:55 a.m. Introduction

10:55 a.m. - 11:15 a.m. Brief Psychotherapy for Maternal Depression: Impact on School Age Children 
Holly Swartz, University of Pittsburgh School of Medicine

11:15 a.m. - 11:35 a.m. Results From a Phase 2 Trial of SAGE-547 in Severe Postpartum Depression 
Samantha Meltzer-Brody, University of North Carolina at Chapel Hill

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:45 a.m. - 12:15 p.m. | Targeting Treatment Needs in Women’s Mental Health*  
Poinciana 3-4 |
| 11:35 a.m. - 11:55 a.m. | Risk of Depressive Relapse in Women Undergoing Treatment for Infertility  
Marlene Freeman, Massachusetts General Hospital |
| 11:55 a.m. - 12:15 p.m. | Discussion |
| 10:45 a.m. - 12:15 p.m. | Model-Based Approaches to Assist Clinical Development of Psychiatric Products  
Salon 1 |

**Chair:** Hao Zhu, US Food and Drug Administration  
**Discussant:** Mitchell Mathis, US Food and Drug Administration

10:45 a.m. - 10:55 a.m. | Introduction |
10:55 a.m. - 11:15 a.m. | Exposure-Response Analysis of Blood Pressure and Heart Rate Changes for Methylphenidate in Healthy Adults  
Yaning Wang, Center for Drug Evaluation and Research, US Food and Drug Administration |
11:15 a.m. - 11:35 a.m. | Population Pharmacokinetic Modeling and Simulation to Determine Dosing Strategies for Long Acting Injectable Antipsychotics  
Hao Zhu, US Food and Drug Administration |
11:35 a.m. - 11:55 a.m. | Shortening the Duration of Acute Schizophrenia Registration Trials is a Possibility  
Islam Younis, US Food and Drug Administration |
11:55 a.m. - 12:15 p.m. | Discussion |
### 10:45 a.m. - 12:15 p.m. Development of Antidepressants With Novel Mechanisms of Action

**Salon 2**

**Chair:** George Papakostas, Massachusetts General Hospital  
**Co-Chair:** Maurizio Fava, Massachusetts General Hospital  
**Discussant:** Carlos Zarate, National Institute of Mental Health

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 a.m.</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 10:55 a.m. - 11:15 a.m. | The Neurogenic Antidepressant Compound, NSI-189, Shows Potential as a Broad Neurotrophic Agent  
Karl Johe, Neuralstem, Inc. |
| 11:15 a.m. - 11:35 a.m. | The Potential Therapeutic Role of Anti-Inflammatory Agents for Mood Disorders  
Giacomo Salvadore, Janssen Pharmaceuticals |
| 11:35 a.m. - 11:55 a.m. | Synaptic and Extrasynaptic GABA-A Receptors as Drug Targets in Postpartum Depression and Major Depressive Disorder: Development of Two Positive Allosteric Modulators  
Stephen Kanes, Sage Therapeutics |
| 11:55 a.m. - 12:15 p.m. | Discussion                                                              |
| 12:15 p.m. - 1:15 p.m. | Early Career Lunch (RSVP Only)  
_Cowrie 1_ |
| 1:15 p.m. - 1:45 p.m. | NIH Diversity Supplement Program*  
_Salon 1_ |

**Chair:** Lynn Morin, NIH/NIAAA

The National Institutes of Health (NIH) Research Supplements to Promote Diversity in Health-Related Research Program, also known as the Diversity Supplement Program provides additional funds to parent awards to improve the diversity of the research workforce by recruiting and supporting students, post-doctorate and eligible investigators from groups that have been shown to be underrepresented in health-related research. This session will offer Investigators the opportunity to learn more about the program in general and specifics to NIAAA. Current and future student candidates are also encouraged to attend to ask questions regarding their current program, requirements and next steps and learn how this program can help advance their careers.

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 2:00 p.m. - 4:00 p.m. | Pharmaceutical Pipeline Presentations  
  Salon 3              |
| **Chair:** Carlos Zarate, National Institute on Mental Health |
| 2:00 p.m. - 2:10 p.m. | Introduction                                                               |
| 2:10 p.m. - 2:20 p.m. | Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response  
  Gregory Sullivan, Tonix Pharmaceuticals, Inc. |
| 2:20 p.m. - 2:30 p.m. | Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor  
  Kimberly Vanover, Intra-Cellular Therapies, Inc. |
| 2:30 p.m. - 2:40 p.m. | Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Cardiac Safety of Extended-Release Viloxazine (SPN-812 ER) in Healthy Adult Subjects  
  Erika Roers, Supernus Pharmaceuticals, Inc. |
| 2:40 p.m. - 2:50 p.m. | SAGE-547 and SAGE-217: Novel Positive Allosteric Modulators of Synaptic and Extrasynaptic GABA-A Receptors Being Investigated in the Treatment of Mood Disorders  
  Stephen Kanes, Sage Therapeutics |
| 2:50 p.m. - 3:00 p.m. | Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses From the Reconnect Study  
  Anita Clayton, University of Virginia |
| 3:00 p.m. - 3:10 p.m. | Results of a Double-Blind, Placebo-Controlled, Tolerability Study of KarXT: A Novel Combination Targeting Muscarinic Acetylcholine Receptors Using Xanomeline With Trospium Chloride to Mitigate Cholinergic Side Effects  
  Stephen Brannan, Karuna |
2:00 p.m. - 4:00 p.m. Pharmaceutical Pipeline Presentations
(continued) Salon 3

3:10 p.m. - 3:20 p.m. A Phase Ib Dose Ranging Study of Direct Nose to Brain Delivery of Neuropeptide Y in Patients With Posttraumatic Stress Disorder
James Murrough, Icahn School of Medicine at Mount Sinai

3:20 p.m. - 3:30 p.m. Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder
Toyin Adewole, Supernus Pharmaceuticals, Inc.

3:30 p.m. - 3:40 p.m. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Thomas A. Macek, Takeda Development Center Americas, Inc.

3:40 p.m. - 3:50 p.m. Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents With ADHD and Glutamatergic Network Gene Mutations
Garry Neil, Aevi Genomic Medicine

3:50 p.m. - 4:00 p.m. Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Maurizio Fava, Massachusetts General Hospital

4:00 p.m. - 4:15 p.m. Break
Americana Foyer
## Individual Research Reports

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:15 p.m. - 5:30 p.m. | Understanding and Optimizing Treatments for Special Populations: Hypersomnolence, Binge Eating Disorder, Pregnant Women With Depression, and Bipolar Depressive Episodes With Psychosis  
*Poinciana 1-2*

**Chair:** Crystal Clark, Northwestern University

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:15 p.m. - 4:20 p.m. | Introduction  
*4:20 p.m. - 4:35 p.m.* Dasotraline for the Treatment of Moderate to Severe Binge Eating Disorder in Adults: Results From a Randomized, Double-Blind, Placebo-Controlled Study  
Bradford Navia, Sunovion Pharmaceuticals, Inc.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:35 p.m. - 4:50 p.m. | The Prevalence and Correlates of Hypersomnolence and Associated Role Impairment in the National Co-Morbidity Survey Replication (NCS-R)  
Bhanu Prakash Kolla, Mayo Clinic

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:50 p.m. - 5:05 p.m. | Optimizing Medication Management for Pregnant Women With Depression  
Katherine Wisner, Northwestern University Feinberg School of Medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 5:05 p.m. - 5:20 p.m. | Treatment Outcomes of Acute Bipolar Depressive Episode With Psychosis  
Marco Antonio Caldieraro, Massachusetts General Hospital

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 5:20 p.m. - 5:30 p.m. | Discussion  
*=$\Rightarrow$ New Investigator Awardee*
### Advances in Schizophrenia Treatment and Assessment  
**Salon 1**

**Chair:** Richard Keefe, Duke University Medical Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 p.m. - 4:20 p.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 4:20 p.m. - 4:35 p.m. | **Risk Factors for Suicidality in Patients With Schizophrenia: A Systematic Review, Meta-Analysis, and Meta-Regression**  
Fang Yang, The University of Texas Health Science Center at Houston |
| 4:35 p.m. - 4:50 p.m. | **Assessing Functional Capacity Using the UCSD Performance-Based Skills Assessment (UPSA-2-VIM) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)**  
Alexandra Atkins, NeuroCog Trials |
| 4:50 p.m. - 5:05 p.m. | **Schizophrenia Polygenic Risk Score Predicts Antipsychotic Treatment Response in Patients With First Episode Psychosis**  
Jianping Zhang, The Zucker Hillside Hospital |
| 5:05 p.m. - 5:20 p.m. | **Lumateperone (ITI-007): Late Stage Clinical Program in Schizophrenia**  
Cedric O’Gorman, Intra-Cellular Therapies, Inc. |
| 5:20 p.m. - 5:30 p.m. | **Discussion**                                                                            |

### Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse  
**Salon 2**

**Chair:** Usman Hameed, Penn State Hershey Medical Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 p.m. - 4:20 p.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 4:20 p.m. - 4:35 p.m. | **Trauma Exposure Moderates the Genetic Overlap Between Alcohol Misuse and Bipolar Disorders in US Army Soldiers**  
Renato Polimanti, Yale University |
4:15 p.m. - 5:30 p.m. Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse  
Salon 2

4:35 p.m. - 4:50 p.m. The Relationship Between Cognitive and Functional Performance and Measures of Neurodegeneration Among Hispanic and White Non-Hispanic Individuals With Normal Cognition, Mild Cognitive Impairment, and Dementia  
Shanna L. Burke, Florida International University

4:50 p.m. - 5:05 p.m. Hazardous Alcohol Intake Alters Brain, Autonomic and Hypothalamic-Pituitary-Adrenal Axis Responses to Stress  
Dongju Seo, Yale University School of Medicine

5:05 p.m. - 5:20 p.m. The Impact of Cerebral Small Vessel Disease in Alzheimer’s Disease and Other Late Life Neurocognitive Disorders  
Walter Swardfager, Sunnybrook Research Institute

5:20 p.m. - 5:30 p.m. Discussion

4:15 p.m. - 5:30 p.m. Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders  
Poinciana 3-4

Chair: Bradley Gaynes, University of North Carolina

4:15 p.m. - 4:20 p.m. Introduction

4:20 p.m. - 4:35 p.m. Differential Adherence to Antipsychotic Medication Impacts Clinical and Functional Outcomes in Antipsychotic-Naïve First-Episode Psychosis Patients: A Longitudinal Study  
Jessica Wojtalik, University of Pittsburgh School of Social Work

4:35 p.m. - 4:50 p.m. A Web-Based Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders  
Samuel Wilkinson, Yale School of Medicine

= New Investigator Awardee
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 4:15 p.m. - 5:30 p.m. (continued) | **Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders**  
*Poinciana 3-4* |
| 4:50 p.m. - 5:05 p.m. | **Screening for Psychiatric Disorders With Self-Administered Questionnaires**  
Mark Zimmerman, Brown University |
| 5:05 p.m. - 5:20 p.m. | **Measuring the Relationship Between Patient Adherence to Atypical Antipsychotics and Their Other Medications**  
Alison Silverstein, Precision Health Economics |
| 5:20 p.m. - 5:30 p.m. | **Discussion** |
| 6:15 p.m. - 7:45 p.m. | **New Investigator Awards Ceremony (Invitation Only)**  
*Cowrie 1-2* |
## AT-A-GLANCE

**Wednesday, May 31, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:30 a.m. - 8:00 a.m. | 18th Annual ASCP Fun Run/Walk  
Open to ALL Attendees! No prior registration necessary.  
St. Moritz Pool |
| 7:00 a.m. - 8:15 a.m. | ASCP Steering Committee Meeting (Invitation Only)  
Crown Conch |
| 7:30 a.m. - 7:00 p.m. | Registration  
Rotunda East |
| 7:30 a.m. - 6:30 p.m. | Speaker Ready Room  
Sundial |
| 7:30 a.m. - 8:30 a.m. | NIA Breakfast Roundtable (Invitation Only)  
Neptune |
| 7:30 a.m. - 8:15 a.m. | ASCP Curriculum Committee Meeting (Invitation Only)  
Venus |
| 7:30 a.m. - 9:00 a.m. | Morning Break  
Americana Foyer |
| 8:30 a.m. - 10:00 a.m. | Regulatory Plenary with FDA & EMA  
Salon 3 |
| 10:00 a.m. - 10:15 a.m. | Break  
Americana Foyer |
| 10:15 a.m. - 11:15 a.m. | ASCP Awards Ceremony and ASCP Lifetime Awardee Talk – David Kupfer: After Fifty Years, All Roads Converge  
Salon 3 |
| 11:15 a.m. - 1:00 p.m. | Poster Session I with Lunch  
Salon 4 |
### 1:00 p.m. - 2:30 p.m.  **Panel Sessions**

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimizing Neuromodulatory and Pharmacologic Approaches to Treatment Refractory Depression*</td>
<td>Poinciana 1-2</td>
<td></td>
</tr>
<tr>
<td>Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations*</td>
<td>Poinciana 3-4</td>
<td></td>
</tr>
<tr>
<td>Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting</td>
<td>Salon 1</td>
<td></td>
</tr>
<tr>
<td>Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*</td>
<td>Salon 2</td>
<td></td>
</tr>
</tbody>
</table>

### 2:30 p.m. - 3:30 p.m.  **FDA 101 Session**

**Salon 3**

### 3:30 p.m. - 3:45 p.m.  **Break**

**Americana Foyer**

### 3:45 p.m. - 5:45 p.m.  **Workshops**

<table>
<thead>
<tr>
<th>Session</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel Applications of Ketamine*</td>
<td>Poinciana 1-2</td>
<td></td>
</tr>
<tr>
<td>Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields*</td>
<td>Poinciana 3-4</td>
<td></td>
</tr>
<tr>
<td>Reducing Health Disparities by Promoting Functional and Life-Satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-Based Care of Depression*</td>
<td>Salon 1</td>
<td></td>
</tr>
<tr>
<td>Tardive Dyskinesia: The Forgotten Adverse Event*</td>
<td>Salon 2</td>
<td></td>
</tr>
</tbody>
</table>

### 5:45 p.m. - 6:45 p.m.  **ASCP Business Meeting & Reception (ASCP Members Only)**

**Poinciana 3-4**

### 6:45 p.m. - 7:45 p.m.  **ASCP Reception**

**Americana Lawn**

*of special interest to clinicians*
FULL SCHEDULE

Wednesday, May 31, 2017

6:30 a.m. - 8:00 a.m.  18th Annual ASCP Fun Run/Walk - Open to ALL Attendees!
                      All participants receive a FREE ASCP T-shirt!
                      *St. Moritz Pool*

7:00 a.m. - 8:15 a.m.  ASCP Steering Committee Meeting (Invitation Only)
                      *Crown Conch*

7:30 a.m. - 8:15 a.m.  ASCP Curriculum Committee Meeting (Invitation Only)
                      *Venus*

7:30 a.m. - 7:00 p.m.  Registration
                      *Rotunda East*

7:30 a.m. - 6:30 p.m.  Speaker Ready Room
                      *Sundial*

7:30 a.m. - 8:30 a.m.  NIA Breakfast Roundtable (Invitation Only)
                      *Neptune*

7:30 a.m. - 9:00 a.m.  Morning Break
                      *Americana Foyer*
8:30 a.m. - 10:00 a.m.   Regulatory Plenary with FDA & EMA
 Salon 3

Chair: Mark Rapaport, Emory University School of Medicine

Presenters:   Tiffany Farchione, US Food and Drug Administration
Islam Younis, US Food and Drug Administration
Luca Pani, European Medicines Agency (EMA)
Valentina Mantua, Italian Medicines Agency (AIFA)

This year’s plenary session will provide updates on major ongoing projects at FDA and EMA.

FDA will present two initiatives. First is a Critical Path Initiative project entitled, “Optimizing Design Elements of Schizophrenia Clinical Trials.” The goals of this project were to assess the feasibility of reducing the number of PANSS items, using time to dropout as a trial endpoint, and shortening trial duration. Topline data from the project will be shared during the plenary. The FDA will also discuss our progress toward revising the Agency guidance on assessment of suicidal ideation and behavior in clinical trials.

EMA will provide a general overview of current activities, including the PRIME (PRIority MEdicines) scheme and planned updates to guidelines.

10:00 a.m. - 10:15 a.m.   Break
Americana Foyer
Awards Presented to:

**Best Paper in the Journal of Clinical Psychiatry Award:** Emil F. Coccaro, University of Chicago
Nominated For: *Toxoplasma gondii Infection: Relationship With Aggression in Psychiatric Subjects*

**Presidential Service Award:** Ira Glick, Stanford University School of Medicine

**2016 Honorific Research Grant Awardee:** Virginie-Anne Chouinard, M.D., Harvard Medical School, McLean Hospital. *See her award-winning research at Poster 50 on Thursday, June 1, 2017 from 12:30 PM – 2:00 PM.*

**Lifetime Awardee:** David Kupfer, University of Pittsburgh School of Medicine/ Western Psychiatric Institute and Clinic

The last 50 years in clinical psychopharmacology have reflected both the major advances in neuroscience and the major frustrations in the clinical application of psychopharmacologic agents. My own voyage has been highlighted by many of the themes illustrative both of these advances and these frustrations. In this presentation, I shall briefly review the evolution of the concept of major depression as an example of diagnostic issues that have characterized this half-century and the accompanying views of prognosis. The use of clinical trials, primarily RCT’s, has led to more precise terminology and methodological advances. The dialectic between dimensional and categorical approaches to diagnosis illustrates other important aspects of this period in psychopharmacology, as does the necessity of identifying biomarkers to track disease, to move in the direction of more precise prognoses and, ultimately, to elucidate underlying etiology.

**11:15 a.m. - 1:00 p.m.**  
**Poster Session I with Lunch**  
*Salon 4*  
*See pages 75-85 for a complete listing of posters.*
### Panel Sessions

1:00 p.m. - 2:30 p.m. **Optimizing Neuromodulatory and Pharmacologic Approaches to Treatment Refractory Depression***

*Poinciana 1-2*

**Chair:** Michael Henry, Massachusetts General Hospital  
**Discussant:** William Potter, National Institute of Mental Health

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 1:10 p.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 1:10 p.m. - 1:30 p.m.  | **Pharmacological Strategies in the Treatment of Resistant Depression**  
                        | Maurizio Fava, Massachusetts General Hospital                           |
| 1:30 p.m. - 1:50 p.m.  | **Optimizing Transcranial Magnetic Stimulation (TMS) Therapy for TRD**  
                        | Joan Camprodon, Harvard Medical School/ Massachusetts General Hospital  |
| 1:50 p.m. - 2:10 p.m.  | **Strategies for Optimizing ECT: Integration of Pharmacology, Anesthesia and Stimulus Parameters.**  
                        | Michael Henry, Massachusetts General Hospital                           |
| 2:10 p.m. - 2:30 p.m.  | **Discussion**                                                          |

1:00 p.m. - 2:30 p.m. **Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations***

*Poinciana 3-4*

**Chair:** Joseph Goldberg, Icahn School of Medicine at Mount Sinai  
**Discussant:** Nina Schooler, SUNY Downstate Medical Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 1:10 p.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 1:10 p.m. - 1:25 p.m.  | **Prevalence of Akathisia, EPS and TD Across Agents and Patient Populations**  
                        | Joseph Goldberg, Icahn School of Medicine at Mount Sinai                |

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 2:30 p.m. (continued)</td>
<td>Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations*</td>
</tr>
</tbody>
</table>
| 1:25 p.m. - 1:40 p.m. | Who's at Risk for Drug-Induced Movement Disorders? A Focus on Diversity of Patient Risk Factors and Clinical Presentations  
Peter Weiden, Alkermes, Inc. |
| 1:40 p.m. - 1:55 p.m. | Treatment Adherence and Antipsychotic-Related Adverse Effects  
Martha Sajatovic, University Hospitals Case Medical Center |
| 1:55 p.m. - 2:10 p.m. | Current and Emerging Treatments for Drug Induced Movement Disorders  
Andrew Cutler, Meridien Research |
| 2:10 p.m. - 2:30 p.m. | Discussion |
| 1:00 p.m. - 2:30 p.m. | Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting  
Salon 1 |

**Chair:** Beatrice Setnik, INC Research  
**Discussant:** Pierre Geoffroy, INC Research

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 1:10 p.m.</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 1:10 p.m. - 1:30 p.m. | Regulatory Considerations in the Assessment of Drug Dependence and Withdrawal in Humans  
Jack Henningfield, Pinney Associates |
| 1:30 p.m. - 1:50 p.m. | Clinical Methods to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation  
Beatrice Setnik, INC Research |

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:00 p.m. - 2:30 p.m. (continued) | Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting  
*Salon 1* |
| 1:50 p.m. - 2:10 p.m. | Practical Considerations Regarding the Administration of Pharmacodynamic Measures to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation  
Denise Milovan, INC Research |
| 2:10 p.m. - 2:30 p.m. | Discussion                                                                                   |
| 1:00 p.m. - 2:30 p.m. | Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*  
*Salon 2* |

**Chair:** Lori Davis, Veterans Affairs Medical Center  
**Discussant:** Richard Shelton, University of Alabama at Birmingham

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 1:10 p.m.</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 1:10 p.m. - 1:25 p.m. | An Evidence Based Review of Early Intervention and Prevention of Posttraumatic Stress Disorder  
Badari Birur, University of Alabama at Birmingham |
| 1:25 p.m. - 1:40 p.m. | An Evidence Based Review of Psychotherapy Interventions for Treatment of Posttraumatic Stress Disorder  
Sheila Rauch, Atlanta VAMC/Emory University School of Medicine |
| 1:40 p.m. - 1:55 p.m. | Clinical Practice Guidelines for the Pharmacotherapy of Posttraumatic Stress Disorder  
Lori Davis, Veterans Affairs Medical Center |

*of special interest to clinicians*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. - 2:30 p.m. (continued)</td>
<td>Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*</td>
<td>Salon 2</td>
</tr>
<tr>
<td>1:55 p.m. - 2:10 p.m.</td>
<td>Translating the Facilitation or Impairment of Fear Acquisition and Extinction Memories in Trauma-, Stressor-, and Anxiety-Related Disorders: Implications for PTSD Treatment</td>
<td>Seth Norrholm, Emory University School of Medicine</td>
</tr>
<tr>
<td>2:10 p.m. - 2:30 p.m.</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>2:30 p.m. - 3:30 p.m.</td>
<td>FDA 101 Session: Care and Feeding of an Investigational New Drug</td>
<td>Salon 3</td>
</tr>
</tbody>
</table>

**Chair:** Keith Kiedrow, US Food and Drug Administration  
**Co-chair:** Hiren Patel, US Food and Drug Administration  
**Presenters:** Kofi Ansah, William Bender, Kimberly Updegraff, US Food and Drug Administration

The Division of Psychiatry Products (DPP) is part of the Office of New Drugs (OND) in the Center for Drug Development and Research (CDER) at the Food and Drug Administration (FDA). The Division reviews matters related to Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for indications ranging from Schizophrenia and Major Depressive Disorder to Autism and Insomnia. As an investigator, it is important to know and understand the definition of an IND as set forth under 21 CFR 312.3, as well as FDA's interpretation. In addition, investigators must be aware of the responsibilities related to IND submission and maintenance and must understand that these responsibilities differ depending on whether the investigator is participating as part of an industry-funded clinical trial or as an individual investigator. For the individual investigator, there are many things to consider such as whether an IND is necessary, what to include in an application, what happens after the application is submitted, and reporting requirements for on-going studies. The FDA has numerous resources available to help investigators navigate the process.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 p.m. - 3:45 p.m.</td>
<td>Break</td>
<td>Americana Foyer</td>
</tr>
</tbody>
</table>

*of special interest to clinicians
## Workshops

### 3:45 p.m. - 5:45 p.m. Novel Applications of Ketamine*

**Poinciana 1-2**

**Chair:** Waguih IsHak, Cedars-Sinai Medical Center and UCLA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m. - 4:00 p.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 4:00 p.m. - 4:25 p.m. | **Intravenous Ketamine for the Treatment of Comorbid Pain and Depression**  
Jonathan Dang, Cedars-Sinai Medical Center |
| 4:25 p.m. - 4:50 p.m. | **Ketamine for Treatment of Depression in Parkinson’s Disease**  
Brigitte Vanle, Cedars-Sinai Medical Center |
| 4:50 p.m. - 5:15 p.m. | **The Challenges of Maintenance and Relapse Prevention After Ketamine IV: The Role of Sublingual Ketamine**  
Waguih IsHak, Cedars-Sinai Medical Center and UCLA |
| 5:15 p.m. - 5:45 p.m. | **Discussion**                                                           |

### 3:45 p.m. - 5:45 p.m. Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields*

**Poinciana 3-4**

**Chair:** Andrea Schneider, Marquette University Law School

*of special interest to clinicians*
3:45 p.m. - 5:45 p.m. Reducing Health Disparities by Promoting Functional and Life-Satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-Based Care of Depression*

*of special interest to clinicians

**Salon 1**

**Chair:** Madhukar Trivedi, UT Southwestern Medical Center  
**Co-Chair:** Manish Jha, UT Southwestern Medical Center

3:45 p.m. - 4:00 p.m. Introduction

4:00 p.m. - 4:25 p.m. Work and Non-Work Related Productivity Improvement With Antidepressant Medications Predicts Long-Term Clinical Outcomes in Outpatients With Major Depressive Disorder  
Madhukar Trivedi, UT Southwestern Medical Center

4:25 p.m. - 4:50 p.m. Changes in Life-Satisfaction With Antidepressant Treatment Predict Long-Term Clinical Outcomes  
Manish Jha, UT Southwestern Medical Center

4:50 p.m. - 5:15 p.m. Policy Implications for Treatment Outcomes of Depressed Patients From Low-Income and Minority Populations  
Michele Guzman, Meadows Mental Health Policy Institute

5:15 p.m. - 5:45 p.m. Discussion

3:45 p.m. - 5:45 p.m. Tardive Dyskinesia: The Forgotten Adverse Event*

**Salon 2**

**Chair:** Jean-Pierre Lindenmayer, New York University

3:45 p.m. - 4:00 p.m. Introduction

4:00 p.m. - 4:20 p.m. What is the Current Prevalence and Incidence of Tardive Dyskinesia?  
John Kane, The Zucker Hillside Hospital
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m. -</td>
<td>Tardive Dyskinesia: The Forgotten Adverse Event*</td>
</tr>
<tr>
<td>5:45 p.m.</td>
<td><em>(continued)</em></td>
</tr>
<tr>
<td>4:20 p.m. -</td>
<td>Do Psychiatric Residents Underrecognize Tardive Dyskinesia?</td>
</tr>
<tr>
<td>4:40 p.m.</td>
<td>Jean-Pierre Lindenmayer, New York University</td>
</tr>
<tr>
<td>4:40 p.m. -</td>
<td>Treatment Landscape of Tardive Dyskinesia: What Works, What Doesn’t,</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>and Why</td>
</tr>
<tr>
<td>5:00 p.m. -</td>
<td>Leslie Citrome, New York Medical College</td>
</tr>
<tr>
<td>5:20 p.m.</td>
<td>New Pharmacologic Interventions for Tardive Dyskinesia: An Update</td>
</tr>
<tr>
<td>5:20 p.m. -</td>
<td>Ira Glick, Stanford University School of Medicine</td>
</tr>
<tr>
<td>5:20 p.m. -</td>
<td>Discussion</td>
</tr>
<tr>
<td>5:45 p.m. -</td>
<td>ASCP Business Meeting &amp; Reception (ASCP Members Only)</td>
</tr>
<tr>
<td>6:45 p.m.</td>
<td>ASCP Reception</td>
</tr>
<tr>
<td>6:45 p.m.</td>
<td>Americana Lawn</td>
</tr>
</tbody>
</table>

*of special interest to clinicians*
### AT-A-GLANCE

**Thursday, June 1, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. - 8:00 a.m.</td>
<td><strong>Federal Agency Liaison Meeting (Invitation Only)</strong></td>
<td>Crown Conch</td>
</tr>
<tr>
<td>7:15 a.m. - 8:15 a.m.</td>
<td><strong>NIA Breakfast Roundtable (Invitation Only)</strong></td>
<td>Neptune</td>
</tr>
<tr>
<td>7:30 a.m. - 6:00 p.m.</td>
<td><strong>Registration</strong></td>
<td>Rotunda East</td>
</tr>
<tr>
<td>7:30 a.m. - 6:30 p.m.</td>
<td><strong>Speaker Ready Room</strong></td>
<td>Sundial</td>
</tr>
<tr>
<td>7:30 a.m. - 9:00 a.m.</td>
<td><strong>Morning Break</strong></td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>8:15 a.m. - 9:45 a.m.</td>
<td><strong>Keynote Plenary: Serving the Needs of the Diverse Population</strong>*</td>
<td>Salon 3</td>
</tr>
<tr>
<td>9:45 a.m. - 10:00 a.m.</td>
<td><strong>Break</strong></td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>10:00 a.m. - 12:30 p.m.</td>
<td><strong>Federal Agency Directors Plenary</strong></td>
<td>Salon 3</td>
</tr>
<tr>
<td>12:30 p.m. - 2:00 p.m.</td>
<td><strong>Poster Session II with Lunch</strong></td>
<td>Salon 4</td>
</tr>
<tr>
<td>2:00 p.m. - 3:30 p.m.</td>
<td><strong>Psychopharmacology State-of-the-Art Updates</strong>*</td>
<td>Salon 3</td>
</tr>
<tr>
<td>3:30 p.m. - 3:45 p.m.</td>
<td><strong>Break</strong></td>
<td>Americana Foyer</td>
</tr>
</tbody>
</table>

*of special interest to clinicians*
### Workshops

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m. - 5:45 p.m.</td>
<td><strong>Workshops</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Rapid-Acting Antidepressants:</strong> Perspective on Issues in Nonclinical and Clinical Development from the Division of Psychiatry Products (DPP), Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td><strong>How to Use the Model Psychopharmacology Curriculum in Various Teachings</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches</strong></td>
</tr>
<tr>
<td>Poinciana 1-2</td>
<td>Salon 1</td>
</tr>
<tr>
<td>Salon 2</td>
<td><strong>ASCP Board of Directors Meeting (Invitation Only)</strong></td>
</tr>
<tr>
<td>Crown Conch</td>
<td><strong>of special interest to clinicians</strong></td>
</tr>
</tbody>
</table>

*of special interest to clinicians*
Thursday, June 1, 2017

FULL SCHEDULE

Thursday, June 1, 2017

7:00 a.m. - 8:00 a.m. Federal Agency Liaison Meeting (Invitation Only)
                    Crown Conch

7:15 a.m. - 8:15 a.m. NIA Breakfast Roundtable (Invitation Only)
                    Neptune

7:30 a.m. - 6:00 p.m. Registration
                    Rotunda East

7:30 a.m. - 6:30 p.m. Speaker Ready Room
                    Sundial

7:30 a.m. - 9:00 a.m. Morning Break
                    Americana Foyer

8:15 a.m. - 9:45 a.m. Keynote Session: Serving the Needs of the Diverse Population*
                    Salon 3

Chair: Marlene Freeman, Massachusetts General Hospital

This Keynote Plenary Session will address disparities and opportunities in treatment engagement across diverse populations, dovetailing with the 2017 ASCP annual meeting theme.

Dr. Roberto Lewis-Fernández will address disparities in psychopharmacology among racial and ethnic minorities. He will present data regarding interventions to overcome specific challenges regarding the barriers at the patient, provider, and organizational level. Dr. Michael Compton will address the societal approaches to disparities, and discuss health promotion policy optimization and social variables. Dr. Andrew Nierenberg will discuss opportunities for patient engagement in research in psychopharmacology and clinical trial methodology. He will discuss the federally funded Mood Disorders Patient Powered Research Network and the Institute of Medicine’s concept of a learning health system.

8:15 a.m. - 8:25 a.m. Introduction

8:25 a.m. - 8:45 a.m. Overcoming Disparities in Treatment Engagement across Diverse Populations
                    Roberto Lewis-Fernández, Columbia University

*of special interest to clinicians
8:15 a.m. - 9:45 a.m. Keynote Session: Serving the Needs of the Diverse Population*
Salon 3

8:45 a.m. - 9:05 a.m. The Social Determinants of Mental Health: What? Who? and How?
Michael Compton, Columbia University

9:05 a.m. - 9:25 a.m. People/Participants/Patients at the Center: Re-Engineering Psychopharmacology Trials
Andrew Nierenberg, Massachusetts General Hospital

9:25 a.m. - 9:45 a.m. Discussion

9:45 a.m. - 10:00 a.m. Break
Americana Foyer

10:00 a.m. - 12:30 p.m. Federal Agency Directors Plenary
Salon 3

Chair: Mark H. Rapaport, Emory University School of Medicine

10:00 a.m. - 10:05 a.m. Introduction

10:05 a.m. - 10:20 a.m. NIAAA Update
Raye Litten, National Institute on Alcohol Abuse and Alcoholism

10:20 a.m. - 10:35 a.m. NINDS Update
Amir Tamiz, National Institute of Neurological Disorders and Stroke

10:35 a.m. - 10:50 a.m. NIMH Update
Josh Gordon, National Institute of Mental Health

10:50 a.m. - 11:05 a.m. NIDA Update
Kevin Walton, National Institute on Drug Abuse

11:05 a.m. - 11:20 a.m. NIH Center for Scientific Review Update
Richard Nakamura, Center for Scientific Review

*of special interest to clinicians
10:00 a.m. - 12:30 p.m.  
Federal Agency Directors Plenary  
Salon 3

11:20 a.m. - 11:35 a.m.  
Research Funding in Mental Health at PCORI  
Grayson Norquist, Patient-Centered Outcomes Research Institute

11:35 a.m. - 11:50 a.m.  
DoD Update  
COL Dennis McGurk, Department of Defense

11:50 a.m. - 12:30 p.m.  
Discussion and Q&A

12:30 p.m. - 2:00 p.m.  
Poster Session II with Lunch  
Salon 4  
See pages 86-96 for a complete listing of posters.

2:00 p.m. - 3:30 p.m.  
Psychopharmacology State-of-the-Art Updates*  
Salon 3

Chair: Holly Swartz, University of Pittsburgh

The purpose of this symposium is to provide an overview of the recent advances in clinical psychopharmacology leading to the development of novel treatments for mood disorders. The session will focus on schizophrenia, anxiety disorders, and neuromodulation.

2:00 p.m. - 2:10 p.m.  
Introduction

2:10 p.m. - 2:30 p.m.  
Schizophrenia: What's New in 2017?  
Nina Schooler, Ph.D., SUNY Downstate Medical Center

2:30 p.m. - 2:50 p.m.  
Update on the Anxiety Disorders  
Mark Pollack, M.D., Rush University Medical Center

2:50 p.m. - 3:10 p.m.  
Neuromodulation  
Sarah Lisanby, M.D., National Institute of Mental Health

3:10 p.m. - 3:30 p.m.  
Discussion

3:30 p.m. - 3:45 p.m.  
Break  
Americana Foyer

*of special interest to clinicians
Workshops

3:45 p.m. - 5:45 p.m.  Rapid-Acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development From the Division of Psychiatry Products (DPP), Food and Drug Administration

Poinciana 1-2

Chair: Javier Muniz, US Food and Drug Administration
Co-Chair: Juliette Toure, Center for Drug Evaluation and Research, US Food and Drug Administration
Discussant: Tiffany Farchione, US Food and Drug Administration

3:45 p.m. - 4:00 p.m.  Introduction

4:00 p.m. - 4:15 p.m.  Rapid-Acting Antidepressants: Perspective on Issues in Non-Clinical and Clinical Development from the Division of Psychiatry Products, Food and Drug Administration

Shiny Mathew, Center for Drug Evaluation and Research, US Food and Drug Administration

4:15 p.m. - 4:30 p.m.  Rapid-Acting Antidepressants: Clinical Trial Design Considerations

Bernard Fischer, FDA/CDER/DPP

4:30 p.m. - 4:45 p.m.  Rapid-Acting Antidepressants: Selection and Timing of Efficacy Endpoints

Michael Davis, US Food and Drug Administration

4:45 p.m. - 5:00 p.m.  Rapid-Acting Antidepressants: Clinical Trial Assessments, Interventions and Procedures to Enhance Subject Safety

Andy Mattai, Center for Drug Evaluation and Research, US Food and Drug Administration

5:00 p.m. - 5:15 p.m.  Rapid-Acting Antidepressants: Expedited Programs for Serious Conditions

Jean Kim, FDA/CDER/DPP

5:15 p.m. - 5:45 p.m.  Discussion
Thursday, June 1, 2017

3:45 p.m. - 5:45 p.m. | How to Use the Model Psychopharmacology Curriculum in Various Teachings

*Salon 1*

**Chair:** Ira Glick, Stanford University School of Medicine

3:45 p.m. - 5:45 p.m. | Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches

*Salon 2*

**Chair:** Crystal Clark, Northwestern University

**Discussant:** Matthew Rudorfer, National Institutes of Health/NIMH

3:45 p.m. - 4:00 p.m. | Introduction

4:00 p.m. - 4:15 p.m. | Mood Symptoms in Pregnant Women With Bipolar Disorder: How Effective is Psychotropic Treatment?

Katherine Wisner, Northwestern University Feinberg School of Medicine

4:15 p.m. - 4:30 p.m. | Risk-Benefit Analysis of Psychotropic Use in Pregnancy: Practical Guidelines for Clinicians From a Forensic Perspective

Cara Angelotta, Northwestern University Feinberg School of Medicine

4:30 p.m. - 4:45 p.m. | New Approaches to the Design and Analysis of Studies Evaluating the Safety of Psychotropic Medications During Pregnancy

Krista Huybrechts, Brigham and Women’s Hospital, Harvard Medical School

4:45 p.m. - 5:00 p.m. | Obstetrical Physiology and Its Impact on Pharmacokinetics

Catherine Stika, Northwestern University Feinberg School of Medicine

5:00 p.m. - 5:15 p.m. | Pharmacokinetics of Lamotrigine and Lithium Across Pregnancy: Evidence to Inform Dose Optimization

Crystal Clark, Northwestern University

5:15 p.m. - 5:45 p.m. | Discussion
6:00 p.m. - 9:00 p.m.  ASCP Board of Directors Meeting
(Invitation Only)
Crown Conch
Friday, June 2, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m. - 12:00 p.m.</td>
<td>Registration</td>
<td>Rotunda East</td>
</tr>
<tr>
<td>7:30 a.m. - 10:30 a.m.</td>
<td>Speaker Ready Room</td>
<td>Sundial</td>
</tr>
<tr>
<td>7:30 a.m. - 9:00 a.m.</td>
<td>Morning Break</td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>8:30 a.m. - 10:00 a.m.</td>
<td>Panel Sessions</td>
<td></td>
</tr>
<tr>
<td>Suicidal Behavior in the Clinical Setting: Relationship Between ADHD, Depression, and Decision-Making Capacity*</td>
<td>Poinciana 1-2</td>
<td>Poinciana 3-4</td>
</tr>
<tr>
<td>Validly and Reliably Measuring Functional Performance in Dementia Patients Across Countries and Languages in Clinical Trials</td>
<td>Poinciana 3-4</td>
<td></td>
</tr>
<tr>
<td>New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials</td>
<td>Salon 1</td>
<td></td>
</tr>
<tr>
<td>Neuromodulation With Transcranial Near-Infrared Light: Controlled Evidence*</td>
<td>Salon 2</td>
<td></td>
</tr>
<tr>
<td>10:00 a.m. - 10:15 a.m.</td>
<td>Break</td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>10:15 a.m. - 11:45 a.m.</td>
<td>Regulatory Wrap-Up Plenary</td>
<td>Salon 3</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Meeting Adjourns</td>
<td></td>
</tr>
</tbody>
</table>

*of special interest to clinicians
FULL SCHEDULE

Friday, June 2, 2017

7:30 a.m. - 12:00 p.m. Registration
Rotunda East

7:30 a.m. - 10:30 a.m. Speaker Ready Room
Sundial

7:30 a.m. - 9:00 a.m. Morning Break
Americana Foyer

Panel Sessions

8:30 a.m. - 10:00 a.m. Suicidal Behavior in the Clinical Setting:
Relationship Between ADHD, Depression, and Decision-Making Capacity
Poinciana 1-2

Chair: Martin Katzman, START Clinic for Mood and Anxiety Disorders
Co-Chair: Tia Sternat, START Clinic for Mood and Anxiety Disorders
Discussant: Larry Klassen, Eden Mental Health Centre

8:30 a.m. - 8:40 a.m. Introduction

8:40 a.m. - 9:00 a.m. Phenotypes of Suicidality in Depressed Patients
Irvin Epstein, University of Toronto

9:00 a.m. - 9:20 a.m. Chronic Anhedonia: A Risk Factor for Attention Deficit Hyperactivity Disorder and Suicidal Behavior in Depressed Adults
Tia Sternat, START Clinic for Mood and Anxiety Disorders

9:20 a.m. - 9:40 a.m. Neurobiological Variance in Suicide Attempt and Ideation: Clinical and Treatment Implications
Martin Katzman, START Clinic for Mood and Anxiety Disorders

9:40 a.m. - 10:00 a.m. Discussion
### 8:30 a.m. - 10:00 a.m. Validly and Reliably Measuring Functional Performance in Dementia Patients Across Countries and Languages in Clinical Trials  
*Poinciana 3-4*

**Chair:** Magdalena Perez, inVentiv Health  
**Co-Chair:** Isabelle Gelinas, McGill University  
**Discussant:** Julie Marsh, inVentiv Health

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 8:40 a.m.    | **Measuring Functional Performance in Individuals on the Dementia Continuum: What to Consider**  
Patricia Belchior, McGill University |
| 9:00 a.m.    | **Linguistically Validating the Disability Assessment in Dementia (DAD) for Use in International Clinical Trials**  
Christelle Giroudet, Mapi Language Services |
| 9:20 a.m.    | **Training and Monitoring Clinicians Administering Functional Assessments in Dementia Global Trials**  
Magdalena Perez, inVentiv Health |
| 9:40 a.m.    | **Discussion**                                                          |

### 8:30 a.m. - 10:00 a.m. New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials  
*Salon 1*

**Chair:** Michael Detke, Indiana University School of Medicine  
**Discussant:** Janet Williams, MedAvante

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 8:40 a.m.    | **NEWMEDS Data on Duplicate and Sequential Enrollment in Clinical Trials and Online Registry to Reduce Duplicate and Sequential Enrollment**  
Jonathan Rabinowitz, Bar-Ilan University |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:30 a.m. - 10:00 a.m. | New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials  
*Salon 1* |
| 8:55 a.m. - 9:10 a.m. | Learning From a Computer Simulated Rater: Lessons in Signal Detection  
Gary Sachs, Bracket |
| 9:10 a.m. - 9:25 a.m. | Clinical Trial Design, Conduct and Analysis Methodology Options to Reduce Risk, Time, Cost, and Enable Signal Detection in the Presence of High Placebo Response and Variability in Neuroscience  
Marc De Somer, PPD |
| 9:25 a.m. - 9:40 a.m. | Expectation Bias and Variance: Challenges to CNS Trial Signal Detection and Some New Technologies to Minimize Them  
Michael Detke, Indiana University School of Medicine |
| 9:40 a.m. - 10:00 a.m. | Discussion |
| 8:30 a.m. - 10:00 a.m. | Neuromodulation With Transcranial Near-Infrared Light: Controlled Evidence  
*Salon 2* |

**Chair**: Paolo Cassano, Massachusetts General Hospital  
**Co-Chair, Discussant**: Dan Iosifescu, Nathan S. Kline Institute/New York University School of Medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m. - 8:40 a.m.</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 8:40 a.m. - 9:00 a.m. | Transcranial Photobiomodulation for Brain Disorders  
Yingying Huang, Harvard Medical School/ Massachusetts General Hospital |
| 9:00 a.m. - 9:20 a.m. | Transcranial Photobiomodulation in Major Depressive Disorder  
Paolo Cassano, Massachusetts General Hospital |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m. - 10:00 a.m.</td>
<td>Neuromodulation With Transcranial Near-Infrared Light: Controlled Evidence</td>
</tr>
<tr>
<td>(continued)</td>
<td>Salon 2</td>
</tr>
<tr>
<td>9:20 a.m. - 9:40 a.m.</td>
<td>Significant Improvement in Cognition in Mild to Moderately-Severe Dementia Cases Treated With Transcranial Plus Intranasal Photobiomodulation: Case Series Report</td>
</tr>
<tr>
<td></td>
<td>Anita Saltmarche, Saltmarche Health &amp; Associates, Inc.</td>
</tr>
<tr>
<td>9:40 a.m. - 10:00 a.m.</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:00 a.m. - 10:15 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td></td>
<td>Americana Foyer</td>
</tr>
<tr>
<td>10:15 a.m. - 11:45 a.m.</td>
<td>Regulatory Wrap-Up Plenary</td>
</tr>
<tr>
<td></td>
<td>Salon 3</td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td>Mark H. Rapaport, Emory University School of Medicine</td>
</tr>
<tr>
<td><strong>Presenters:</strong></td>
<td>Tiffany Farchione, US Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td>Islam Younis, US Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td>Luca Pani, European Medicines Agency</td>
</tr>
<tr>
<td></td>
<td>Valentina Mantua, Italian Medicines Agency (AIFA)</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Meeting Adjourns</td>
</tr>
</tbody>
</table>
Wednesday, May 31, 2017
Poster Session I with Lunch
Salon 4
11:15 a.m. - 1:00 p.m.

W1. Quillivant XR in Children With Autism Spectrum Disorder and ADHD: Dose Effects on ADHD Symptoms and Functioning
Mark Stein*, University of Washington
Soo-Jeong Kim, William French, Lindsay Miller, Sophia Shonka, Jennifer Strickland

W2. Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder
Toyin Adewole*, Supernus Pharmaceuticals, Inc.
Scott Brittain, Janet Johnson, Tesfaye Liranso, Robert Findling

W3. Anxiety as a Confounding Symptom in ADHD Trials
Tammy Steans*, Psychiatric & Behavioral Solutions
Frederick Reimherr, Bennett Steans, Thomas Gift, Barrie Marchant

W4. Glutamatergic Network Gene Mutations in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Liza Squires*, Aevi Genomic Medicine
Josephine Elia, Celia Kim, Munir Khan, Diego Mazzotti, Hakon Hakonarson, Colleen Anderson, David Fitts

W5. Do Opiate Antagonists Interfere With the Clinical Benefits of Stimulants in ADHD? A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone
Joseph Biederman*, Massachusetts General Hospital
Thomas Spencer, Pradeep Bhide, Maura Fitzgerald, Amy Yule, Stephen Faraone

W6. Effect of Sedative Hypnotic Medications on Sleep in Opioid-Dependent Subjects on Buprenorphine
Venkatesh Krishnamurthy*, Penn State Milton S. Hershey Medical Center
Alissa Coffey, Sanjay Yadav, Lan Kong, Alexndros Vgontzas, Edward Bixler, Douglas Leslie, Roger Meyer

 (*)(= New Investigator Awardee, *= Pharmaceutical Pipeline Presentation)
W7. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a Noribogaine Multiple-Dose Regimen in Opioid-Dependent Subjects
Pierre Geoffroy*, INC Research

W8. Adolescent Social Stress Results in Sex-Specific Transcriptional Reprogramming of the Medial Amygdala, a Critical Region for Sex Differences in Reward
Deena Walker*, Icahn School of Medicine at Mount Sinai
Immanuel Purushothaman, Michael Cahill, Casey Lardner, Saima Machlovi, Erin Calipari, Hannah Cates, Rosemary Bagot, Catherine Pena, Georgia Hodes, Scott Russo, Eric Nestler

W9. Identifying Sub-Populations of Heavy Drinkers: A Sweet Road to a Better Phenotypic Characterization?
Sofia Bouhlal*, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institutes of Health
Mehdi Farokhnia, Mary Lee, Lorenzo Leggio

W10. A Proof of Concept Trial of a Novel Combination of Methylphenidate and Ondansetron for Treatment of Stimulant Use Disorder
Ashwin Patkar*, Duke University Medical Center
Steven Szabo, Shein Chow, Tong Lee

Emily Olfson*, Child Study Center, Yale School of Medicine
Krysten Bold, Lisa Fucito, Ralitza Gueorguieva, Peter Jatlow, Allen Zweben, Stephanie O’Malley

W12. The Role of the Black Church in Improving Treatment Access for Blacks With Substance Use Disorders
Ayana Jordan*, Yale University School of Medicine

Michael Cronquist Christensen*, H. Lundbeck A/S
Henrik Loft, Ioana Florea, Roger McIntyre

= New Investigator Awardee  *= Pharmaceutical Pipeline Presentation
Laura Politte*, University of North Carolina at Chapel Hill
Christopher McDougle, Lawrence Scahill, Janet Figueroa, Courtney McCracken

W15. Neuroinflammatory Signature of Treatment Response to Ketamine in Patients With Treatment-Resistant Depression
Simmie Foster*, Massachusetts General Hospital & Harvard Medical School
Chelsea Dale, Abigail Archibald, Joey Cheung, Kerry Ressler, Maurizio Fava, Dawn Ionescu

W16. A Study of Metabolic Disturbance in Adolescent Patients With Bipolar Disorder
Hanjing Emily Wu*, University of Texas Health Science Center at Houston
Teresa Pigott

W17. Course of Two Common Adverse Events in Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder During a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
Pedro Such*, H. Lundbeck A/S
Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Peter Hertel, Phyllis Salzman, Robert McQuade, Margaretta Nyilas, William H. Carson

Martha Sajatovic*, University Hospitals Case Medical Center
Susan Legacy, Matthew Byerly, Christoph Correll, John Kane, Faith DiBiasi, Heather Fitzgerald, Ruth Ross

W19. Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder, a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study: Effects on Types of Recurrence and on Recovery
Joan Amatniek*, Otsuka Pharmaceutical Development and Commercialization, Inc.
Joseph Calabrese, Raymond Sanchez, Na Jin, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Robert McQuade, Margaretta Nyilas, William H. Carson

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
W20. Network Analysis of Depressive and Manic Symptoms in STEP-BD Study  
Cynthia Siu, COS & Associates, Ltd.

W21. Use of Recommended Therapies Following a New Anxiety Diagnosis in Children and Adolescents  
Greta Bushnell*, University of North Carolina at Chapel Hill  
Bradley Gaynes, Scott Compton, Stacie Dusetzina, Alan Brookhart, Til Stürmer

W22. Are Self-Report Scales as Effective as Clinician Rating Scales in Measuring Treatment Response in Routine Clinical Practice?  
Mark Zimmerman*, Brown University  
Emily Walsh, Michael Friedman, Daniela Boerescu, Naureen Attiullah

W23. Expanding the Brief Assessment of Cognition (BAC-App) for Use in Screening for MCI Due to AD  
Alexandra Atkins*, NeuroCog Trials  
Anzalee Khan, Tina Tseng, Adam Vaughan, Christopher Randolph, Harrison John, Brian Saxby, Philip Harvey, Meera Narasimhan, Tom Patterson, Richard Keefe

W24. SAGE-217, A Novel Positive Allosteric Modulator of Synaptic and Extrasynaptic GABA-A Receptors: Phase 1 Single- and Multiple-Ascending Dose Results  
Stephen Kanes*, Sage Therapeutics  
George Nomikos, Mike Quirk, Shane Raines, James Doherty, Ethan Hoffmann, Abdul Sankoh, Helen Colquhoun

W25. SAGE-547 and SAGE-217: Novel Positive Allosteric Modulators of Synaptic and Extrasynaptic GABA-A Receptors Being Investigated in the Treatment of Mood Disorders  
Stephen Kanes*, Sage Therapeutics  
Helen Colquhoun, James Doherty, Shane Raines, Ethan Hoffmann, David Rubinow, Samantha Meltzer-Brody, A.J. Robichaud

W26. Efficacy and Safety of Initially Intramuscular Injection Scopolamine in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial  
Le Xiao*, Beijing Anding Hospital, Capital Medical University  
Jing-jing Zhou, Xue-quan Zhu, Jian Yang

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
W27. Lower Confidence Diagnostic Assignment is Associated With Increased Noise in Efficacy Ratings: An International Analysis
Joan Busner*, Penn State College of Medicine
Marcela Roy, Margot Oakley, Alan Kott, Pamela Elias, Michael Scafidi

W28. Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Maurizio Fava*, Massachusetts General Hospital
Marlene Freeman, Martina Flynn, Heidi Judge, Bettina Hoeppner, Cristina Cusin, Dawn Ionescu, Sanjay Mathew, Lee Chang, Dan Iosifescu, James Murrough, Charles Debbattista, Alan Schatzberg, Madhukar Trivedi, Manish Jha, Gerard Sanacora, Samuel Wilkinson, George Papakostas

W29. Clozapine Clinics as Models for Reverse Integrated Care Delivery to Reduce Medical Mortality and Improve Safety in Patients With Serious Mental Illness
Oliver Freudenreich*, Massachusetts General Hospital
Sarah MacLaurin, Kelly Irwin, Lauren Donahue, Ben Macri, Benjamin Brent, Leah Namey, Hannah Brown, Abigail Donovan, Corinne Cather, Daphne Holt

W30. Association of Bipolar Illness Course With Family History of Alcoholism, Bipolar Disorder, or Both Conditions in First Degree Relatives of Adults With Co-Occurring Bipolar Disorder and Alcohol Dependence
Bryan Tolliver*, Medical University of South Carolina
Helena Brenner, Delisa Brown, Prisciandaro James

W31. Quit Rates of Depressed vs Euthymic Smokers: Is There a Difference?
Ahmad Hameed*, Penn State College of Medicine
Susan Valdheer, Usman Hameed, Ayesha Ahmad, Jonathan Foulds

W32. ITI-333: A Novel Modulator of Serotonin, Dopamine, and Mu Opiate Receptors for the Treatment of Mood Disorders
Kimberly Vanover*, Intra-Cellular Therapies, Inc.
Gretchen Snyder, Peng Li, Wei Yao, Stephanie Cruz, Lawrence Wennogle, Sharon Mates, Robert Davis

= New Investigator Awardee  ⚫ = Pharmaceutical Pipeline Presentation
W33. Designing a Randomized Placebo Controlled Cross-Over Trial Investigating Nabilone as a Treatment for Agitation in Patients With Moderate-to-Severe Alzheimer’s Disease
   Krista Lanctôt*, Sunnybrook Health Science Centre
   Myuri Ruthirakuhan, Eleenor Abraham, Chelsea Sherman, Paul Verhoeff, Alex Kiss, Ana Andreazza, Sandra Black, Nathan Herrmann

W34. Challenges in the Translation of the Neuropsychiatric Inventory (NPI) Into 74 Languages
   Caroline Anfray*, Mapi Research Trust
   Jeffrey Cummings, Stefania Vasarri, Christelle Giroudet

W35. Relapse Prevention With Levomilnacipran ER in Adults With Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
   Suresh Durgam*, Allergan
   Changzheng Chen, Raffaele Migliore, Prakash Chandran, Michael Thase

W36. Does Early Improvement With Vilazodone Predict Response and Remission in Patients With MDD?
   Ken Kramer*, Allergan
   Suresh Durgam, Cheng-Tao Chang, Carl Gommoll, John Edwards, Arifulla Khan

W37. Assessment in Work Productivity and the Relationship With Cognitive Symptoms (AtWoRC): Primary Analysis From a Canadian Open-Label Study of Vortioxetine in First Treatment and Switch Patients With Major Depressive Disorder
   Pratap Chokka*, Chokka Center
   Joanna Bougie, Emmanouil Rampakakis, Jean Proulx

W38. Exploration of the Insular Role in Psychological and Physical Pain in Acute Suicidality
   Ricardo Caceda*, Psychiatric Research Institute, University of Arkansas for Medical Sciences
   Andrew James, Zachary Stowe, Pedro Delgado, Clint Kilts

   Vanessa Perez*, Takeda Development Center Americas, Inc.
   Elizabeth Merikle, Wei Zhong, Christina Kurre Olsen, William Jacobson

= New Investigator Awardee  * = Pharmaceutical Pipeline Presentation
W40. A Novel Use of the Goal Attainment Scale After Change to Vortioxetine in the Treatment of Major Depressive Disorder
Sagar Parikh*, University of Michigan, Ann Arbor
Lisa Mucha, Sara Sarkey, Jen Schuster, Anna Eramo, Maggie McCue, Clément François

W41. Vortioxetine and Suicidal Ideation and Behavior in Adults With Major Depressive Disorder
Atul Mahableshwarkar*, Takeda Development Center Americas, Inc.
John Affinito, Paula Jacobsen, Judith Xu, George Nomikos

W42. An Open Label Trial of Dextromethorphan for Depression in Psychiatric Inpatients
Eric Brueckner*, Medical University of South Carolina
Prisciandaro James, Bryan Tolliver

W43. Cost-Effectiveness Evaluation of Depressive and Cognitive Outcomes of Vortioxetine in Patients in the United States With Major Depressive Disorder Switching From First Antidepressant Therapy
Larry Ereshefsky*, Follow the Molecule: CNS Consulting, LLC
Kokuvi Atsou, Benjamin Briquet, Françoise Diamand, Melanie Brignone, Lisa Mucha, Natalya Danchenko, Clément François

W44. Effect of Adjunctive Brexpiprazole on Metabolic Parameters in Elderly Patients With Major Depressive Disorder: Analysis of an Open-Label, Long-Term, Flexible-Dose Study
Jacquelyn Canning*, Otuska
Ross Baker, Nanco Hefting, Doris Zhang, Mary Hobart

W45. Intermittent Explosive Disorder: DSM-5 Diagnosis Primed for a Pharmacotherapeutic Breakthrough?
John Umhau*, US Food and Drug Administration
Bernard Fischer, Greg Dubitsky, Andy Mattai, Brian Miller, Jean Kim, Michael Davis

W46. Concomitant Use of Atypical Antipsychotics With Leading Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus: A Population-Based Study of Medicaid Insured Youth
Mehmet Burcu*, University of Maryland, Baltimore
Julie Zito, Daniel Safer

= New Investigator Awardee  ★ = Pharmaceutical Pipeline Presentation
W47. Healthcare Professionals’ Satisfaction With a Digital Medicine System in an Open-Label Study of Adult Patients Treated With Oral Aripiprazole
Ross Baker*, Otsuka
Timothy Peters-Strickland, Cathy Zhao, Tao Wang, Margaretta Nyilas, Claudette Brewer, Erica Lawson, Raymond Sanchez

W48. Do Suicidality Phenomena Follow a Linear or a Non-Linear Progression Over Time?
David Sheehan*, University of South Florida College of Medicine
Jennifer Giddens

W49. Enhancing Subjects’ Awareness of Key Placebo Response Factors: The Importance of Implementing a Brief Educational Placebo Response Video
Howard Hassman*, Hassman Research Institute, LLC
Elan Cohen, Shawn Hossain, Paula Amerman, Ashok Joseph, Kimberly Myers

W50. A Model Psychopharmacology Curriculum for Teachers of Psychiatric Residents
Ira Glick*, Stanford University School of Medicine

W51. Pimavanserin for the Treatment of Parkinson’s Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Leslie Citrome*, New York Medical College
James Norton, Kathy Chi-Burris, George Demos

W52. Independent Predictors of Hospitalization in First Episode Psychosis: Baseline Results From the NIMH-ETP Study
Jose M. Rubio*, The Zucker Hillside Hospital
Nina Schooler, Delbert Robinson, Christoph Correll, John Kane

W53. Plasma Cotinine is Positively Correlated With Scores on the NIH Toolbox Cognitive Measures in Patients With Schizophrenia
Benjamin Naovarat*, UT Houston Medical School
Olaoluwa Okusaga

W54. Efficacy of Cariprazine in Patients With Bipolar Mania by Baseline Symptom Severity
Irma Saliu*, Allergan
Lakshmi Yatham, Willie Earley, Cheng-Tao Chang, Ágota Barabássy

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
W55. Efficacy of Cariprazine in Subgroups of Bipolar Patients With Manic Episodes, Mixed Episodes, and With or Without Psychotic Symptoms
Mehul Patel*, Allergan
Eduard Vieta, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Willie Earley

W56. Efficacy of Cariprazine on Negative Symptoms in Acutely Ill Patients With Schizophrenia: A Pooled, Post Hoc Analysis
Willie Earley*, Allergan
Hua Guo, Balázs Szatmári, György Németh, Henry Nasrallah, David Daniel, Mehul Patel

W57. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post-Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial
Steven Potkin*, University of California, Irvine, School of Medicine
Christoph Correll, Cheng-Tao Chang, Balázs Szatmári, István Laszlovszky, Willie Earley

W58. ALKS 3831 Attenuates Dose-Dependent, Olanzapine-Induced Weight Gain in Adults With Schizophrenia: Analysis From a Phase 2, Randomized, Olanzapine-Controlled Study
Lauren DiPetrillo*, Alkermes
Ying Jiang, Asif Paker, Peter Weiden, Sanjeev Pathak, David McDonnell, Bernard Silverman

Rajiv Radhakrishnan*, Yale School of Medicine
Patrick Skosnik, Sjoerd Finnema, Renee Rotolo, Kimberlee Forselius-Bielen, Gina Creatura, Nabeel Nabulsi, Richard Carson, Deepak D’Souza

W60. Variable Free Fatty Acid Composition Associated With SREBF in Schizophrenia Participants Taking Atypical Antipsychotics
Kristen Ward*, University of Michigan
Kathleen Stringer, Vicki Ellingrod

W61. Evaluation of the Potential for Concomitant Medications to Affect Valbenazine Pharmacokinetics
Gordon Loewen*, Neurocrine Biosciences, Inc.
Rosa Luo, Evan Smith, Grace Liang, Haig Bozigian, Christopher O’Brien

= New Investigator Awardee  ★ = Pharmaceutical Pipeline Presentation
W62. Neurocognition and Duration of Untreated Psychosis in First Episode Psychosis: Findings From the RAISE-ETP Study
Srinath Gopinath*, SUNY Health Science Center at Brooklyn
Jeremy Weedon, Nina Schooler

W63. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Thomas A. Macek*, Takeda Development Center Americas, Inc.
Maggie McCue, Xinxin Dong, Elizabeth Hanson, Paul Goldsmith, John Affinito, Atul Mahabaleshwarkar

W64. Measuring the Elements of Desire in the Bremelanotide Reconnect Study
Robert Jordan*, Palatin Technologies, Inc.
Dennis Revicki, Stanley Althof, Leonard Derogatis, Hilary Wilson, Johna Lucas

W65. The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Major Malformations
Lee Cohen*, Massachusetts General Hospital
Adele Viguera, Marlene Freeman, Alexandra Sosinsky, Gina Savella, Laura Cheng, David Chitayat, Sonia Hernandez-Diaz

W66. Assessing the Adequacy of the Blind: An Analysis of Data in IV Ketamine for Rapid Treatment of Depression Study
Frances Cena*, Baylor College of Medicine
Sanjay Mathew

W67. Body Temperature Rises Following Successful ECT Treatment of Depression: Does Body Temperature Decline During Depression Due to Dysfunctional Thermoregulatory Pathways?
Alexander Chen*, Saint Louis University School of Medicine
Henry Nasrallah

W68. Using an Artificial Intelligence Platform on Mobile Devices to Monitor and Increase Adherence in Subjects With Schizophrenia
Adam Hanina*, AiCure
Laura Shafner, Markus Abt, Russell Kinch, Paul Tamburri, Daniel Umbricht

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
W69. A Pilot Study of Acute Anti-Psychotic-Induced Blood Pressure Changes Among Psychiatric Inpatients
Obiora Onwuameze*, Southern Illinois University School of Medicine
Jeffrey Bennett, Jonathan Yost

W70. Are There Cultural Differences in Depression Symptom Expression as Measured by the HAMD-17 in Patient Cohorts in North America and Eastern Europe/Russia?
William Yavorsky*, Cronos CCS
Kristy Woianski, Nina Engelhardt, Cynthia McNamara, Francisco Burger, Guillermo DiClemente

W71. Clin301-203: A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Ronald Marcus*, Cerecor
Arifulla Khan, Michael Liebowitz, Eileen McNulty, Heather Fraser

W72. Marijuana - Is it a Medicine?
Maryam Davari*, Central Michigan University
Thersilla Oberbarnscheidt

W73. Lauflumide (R)-(−) (NLS-4): A New Potent Wake-Promoting Agent
Mehdi Tafti*, University of Lausanne
Gianina Luca

W74. A Novel Vasopressin 1a Receptor Antagonist in Phase II Development for Multiple Disorders of Stress, Mood, and Behavior
Neal Simon*, Azevan Pharmaceuticals, Inc.
Michael Brownstein, Shi-fang Lu, Christophe Guillon, Ned Heindel

= New Investigator Awardee  ★ = Pharmaceutical Pipeline Presentation
Thursday, June 1, 2017
Poster Session II with Lunch
Salon 4
12:30 p.m. - 2:00 p.m.

T1. Formal Cardiac Screening Prior to Initiating Stimulant Medication in ADHD Child and Adolescent Minority Population: A Dual Assessment in an Inner-City Teaching Outpatient Clinic
Shaheen Alam*, Brookdale University Hospital & Medical Center
Marian Moca

T2. Efficacy and Safety of HLD200, a Novel Delayed-Release and Extended-Release Methylphenidate Formulation, in Children With Attention-Deficit/Hyperactivity Disorder: Results From a Pivotal Phase 3 Trial
Floyd Sallee*, Ralph H. Johnson VAMC
Steven Pliszka, Valerie Arnold, Andrea Marraffino, Norberto DeSousa, Bev Incledon, Timothy Wilens, Jeffrey Newcorn

T3. Stimulant Medication Versus Behavioral Parent Training Effects on Mothers With ADHD
Mark Stein*, University of Washington
William French, Jennifer Strickland, Erin Schoenfelder, Samuel Zinner, Lindsay Miller, Tyler Sasser, Andrea Chronis-Tuscano

T4. Effect of Baseline Inflammatory Biomarker (hs-CRP) on Response to Lurasidone Treatment in Patients With Bipolar Depression: An Exploratory Analysis
Andrei Pikalov*, Sunovion Pharmaceuticals, Inc.
Charles Raison, Cynthia Siu, Ken Koblan, Antony Loebel

T5. Abnormal Fear Circuitry in ADHD: A Controlled Magnetic Resonance Imaging Study
Joseph Biederman*, Massachusetts General Hospital
Andrea Spencer, Marie-France Marin, Mohammed Milad, Thomas Spencer

T6. Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents With ADHD and Glutamatergic Network Gene Mutations
Garry Neil*, Aevi Genomic Medicine
Robert Findling, Colleen Anderson, David Fitts, Liza Squires

= New Investigator Awardee  *= Pharmaceutical Pipeline Presentation
T7. Dysregulation of the Histone Demethylase KDM6B in Alcohol Dependence is Associated With Epigenetic Regulation of Inflammatory Signaling Pathways  
Zane Zeier*, Miller School of Medicine, University of Miami  
Andrea Johnstone, Nadja Andrade, Estelle Barbier, Markus Heilig, Claes Wahlestedt

T8. Epigenetic Mechanisms in Alcohol Use Disorder Quantified by Non-Invasive PET Imaging  
Changning Wang*, Harvard University/Massachusetts General Hospital

T9. Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response  
Gregory Sullivan*, Tonix Pharmaceuticals, Inc.  
Judith Gendreau, Michael Gendreau, Jean Engels, Ashild Peters, Perry Peters, Seth Lederman

T10. A Phase Ib Dose Ranging Study of Direct Nose to Brain Delivery of Neuropeptide Y in Patients With Posttraumatic Stress Disorder  
James Murrough*, Icahn School of Medicine at Mount Sinai  
Sehrish Sayed, Nicholas Van Dam, Sarah Horn, Marin Mautz, Michael Parides, Sara Costi, Katherine Collins, Dan Iosifescu, Aleksander Mathé, Steven Southwick, Adriana Feder, Dennis Charney

T11. Role of Soterogram Measuring Arterial Compliance in Psychiatry  
Maju Koola*, George Washington University, School of Medicine and Health Sciences

Laura M. Hack*, Emory University School of Medicine  
Tanja Jovanovic, Sierra Carter, Kerry Ressler, Alicia Smith

T13. Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder: A Blinded, Placebo-Controlled, Randomized Study: Clinical Evaluation of Bipolar Symptoms  
Pedro Such*, H. Lundbeck A/S  
Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Peter Hertel, Phyllis Salzman, Robert McQuade, Margaretta Nyilas, William H. Carson

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
**T14.** Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder: A Blinded, Placebo-Controlled, Randomized Study; Effects on Symptoms and Functioning
Na Jin*, Otsuka Pharmaceutical Development & Commercialization, Inc. Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Phyllis Salzman, Robert McQuade, Margaretta Nyilas, William H. Carson

**T15.** Safety of Lurasidone in Adolescents With Schizophrenia: Interim Analysis of a 24-Month, Open-Label Extension Study
Michael Tocco*, Sunovion
Christoph Correll, Celso Arango, Robert Goldman, Josephine Cucchiaro, Ling Deng, Antony Loebel

**T16.** Effectiveness of Lurasidone in Adolescents With Schizophrenia: Interim Analysis of a 24-Month, Open-Label Extension Study
Michael Tocco*, Sunovion
Celso Arango, Christoph Correll, Robert Goldman, Josephine Cucchiaro, Ling Deng, Antony Loebel

**T17.** Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Cardiac Safety of Extended-Release Viloxazine (SPN-812 ER) in Healthy Adult Subjects
Erika Roers*, Supernus Pharmaceuticals, Inc.
Toyin Adewole, Janet Johnson, Scott Brittain

**T18.** The Prominent Role of Clinical Pharmacology and Dosing in PMAs of Approved NMEs in the Last Ten Years
William Bender*, US Food and Drug Administration

**T19.** A Clinically Useful Screen for Attention-Deficit/Hyperactivity Disorder in Adult Psychiatric Outpatients
Mark Zimmerman*, Brown University
Eugenia Gorlin, Kristy Dalrymple, Iwona Chelminski

**T20.** Serving the Needs of Our Diverse Population: It All Begins With Recruitment!
Charles Wilcox*, Pharmacology Research Institute [PRI]
Daniel Grosz, My-Linh Tong, David Rosenberg, Judy Morrissey, Don DeFrancisco, Clifford Feldman, Mellissa Henry, Lynn Badgett, Nader Oskooilar

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
Posters

Ashwin Patkar*, Duke University Medical Center
Robert Millet, Philip Radford

T22. A Pilot Study of SD-809 (Deutetrabenazine) in Tics Associated With Tourette Syndrome
Barbara Coffey*, Icahn School of Medicine at Mount Sinai
Joseph Jankovic, Joohi Jimenez-Shahed, Cathy Budman, Tanya Murphy, David Shprecher, David Stamler

T23. The Nocebo Phenomenon in a Series of First-Time-In-Human, Double-Blind, Placebo-Controlled, Single Ascending-Dose Trials of CNS Active Agents
Christina Charriez*, Dart NeuroScience
David Carpenter, Jeffery Anderson, Rebecca Crean, Joseph Djan, Jessica Berrett, Jodi Parsons, Jon Ruckle, Philip Perera

T24. Tolerability and Efficiency of Desvenlafaxine in Methadone Maintained Patients Suffering From Major Depressive Disorder
Cynthia El Hage*, Centre of Research of University of Montréal Hospital Center; University of Montréal
Maykel Ghabrash, Simon Dubreucq, Clairélaine Ouellet-Plamondon, Suzanne Brissette, Paul Lespérance, Julie Bruneau, François Lespérance, Didier Jutras-Aswad

T25. Data Surveillance to Improve Endpoint Assessment in Global Alzheimer's Disease
Theresa Shackleford*, ePharmasolutions

T26. Translation of the Zarit Burden Interview 22 Items (ZBI-22) Into 95 Languages: Challenges and Importance of the Conceptual Definition of the Original Version
Caroline Anfray*, Mapi Research Trust
Steven Zarit, Stefania Vasarri, Christelle Giroudet

T27. The Residual Symptoms and Functioning of Major Depressive Patients After Partial Response to Acute Antidepressant Treatment in Clinical Setting
Le Xiao*, Beijing Anding Hospital, Capital Medical University
Lei Feng, Xue-quan Zhu, Jing-jing Zhou

bracht = New Investigator Awardee  ★ = Pharmaceutical Pipeline Presentation
T28. Antidepressant Augmentation and Co-Initiation Treatment in Acute Major Depressive Disorder: A Systematic Review, Meta-Analysis and Metaregression Analysis
Britta Galling*, The Zucker Hillside Hospital
Christoph Correll

T29. Prevalence of Subtherapeutic Prescribing of Antidepressants in the United States
Mary March*, inVentiv Health
Kristina Bertzos, Chris Brady, Jason Fox

T30. Mechanisms of Pain and Opioid Induced Hyperalgesia
Maryam Davari*, Central Michigan University
Thersilla Oberbarsnseidt

T31. Prevalence, Cost of Care, and Treatment Patterns for Major Depressive Disorder Related Hospitalizations
Ken Kramer*, Allergan
Sanjida Ali, Pamela Landsman-Blumberg, Marla Kugel

T32. Ex Vivo Inflammatory Response Patterns Among Non-Medicated Depressed Patients
Marzieh Majd*, Pennsylvania State University
Jody Greaney, Erika Saunders, Christopher Engeland

T33. Adjunctive Brexpiprazole Effects on Weight According to Antidepressant Treatment (ADT) in Short-Term Major Depressive Disorder Studies
Jehan Marino*, Otsuka America
Peter Zhang, Catherine Weiss, Emmanuelle Weiller, Mary Hobart

T34. Long-Term Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder (MDD) – Pooled Analysis of Two Short-Term Placebo-Controlled Studies and of an Open-Label, Long-Term Extension Study
Catherine Weiss*, Otsuka Pharmaceutical Development & Commercialization, Inc.
Emmanuelle Weiller, Peter Zhang, Na Jin, Ross Baker, Mary Hobart

= New Investigator Awardee  ✭ = Pharmaceutical Pipeline Presentation
T35. What is the Overlap Between Subjective and Objective Cognitive Impairment in Major Depressive Disorder (MDD)?
Maurizio Fava*, Massachusetts General Hospital
William Jacobson, Wei Zhong, Richard S.E. Keefe, Christina Kurre Olsen, Judith Jaeger

T36. Metabolic and Cellular Distress Gene Expression Patterns are Associated With Treatment Resistance and Reversed by Deep Brain Stimulation in Rodent Model
Kriti Gandhi*, Mayo Clinic
Sutor Shari, Mark Frye, Susannah Tye

T37. Adjunctive Brexpiprazole in Patients With MDD and Anxiety Symptoms: Results From Post-Hoc Analyses of Three Placebo-Controlled Studies
Emmanuelle Weiller*, H. Lundbeck A/S
Anna-Greta Nylander, Catherine Weiss, Peter Zhang, Mary Hobart

T38. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depressive Disorder
Bashkim Kadriu*, National Institute of Mental Health
Philip Gold, David Luckenbaugh, Rodrigo Machado-Vieira, Carlos Zarate, Jr.

T39. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study
Anup Sharma*, University of Pennsylvania
Marna Barrett, Andrew Cucchiara, Nalaka Gooneratne, Michael Thase

T40. A Novel Approach to Relapse Prevention Studies in the Treatment of Major Depressive Disorder: A Phase 4 Study With Vortioxetine
Paula Jacobsen*, Takeda Development Center Americas, Inc.
Wei Zhong, George Nomikos

T41. Relationship Between Sexual Abuse and Suicidality: What is the Evidence?
Ahmad Hameed*, Penn State College of Medicine
Michael Mitchell, Eric Youngstrom, Roger Meyer, Alan Gelenberg

= New Investigator Awardee  🌟 = Pharmaceutical Pipeline Presentation
T42. Neurochemical Alterations Following Supplementation With a Putative Caloric Restriction Mimetic Blend of Nutrients and Phytochemicals
Chandni Sheth*, University of Utah Medical School, Brain Institute
Angela Mastouldis, Shelly Hester, Steven Wood, Erin McGlade, Perry Renshaw, Deborah Yurgelun-Todd

T43. A Multicenter, 8-Week, Open-Label Study to Assess Usability of a Digital Medicine System in Adult Patients With Schizophrenia Treated With Oral Aripiprazole
Timothy Peters-Strickland*, Otsuka Pharmaceutical
Alex Kopelowicz, Ross Baker, Cathy Zhao, Raymond Sanchez, Margaretta Nyilas, Claudette Brewer, Erica Lawson

T44. A Classification of Suicidality Disorder Phenotypes
David Sheehan*, University of South Florida College of Medicine
Jennifer M. Giddens

T45. Medication Non-Adherence in Older Patients Prescribed Antipsychotic Medications
Mancia Ko*, Ingenuity Health
Thomas Smith

T46. NIMH IRP Translational Neuropsychopharmacology Initiative
Janet Clark*, NIMH/NIH
Susan Amara

*T47. Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor
Kimberly Vanover*, Intra-Cellular Therapies, Inc.
Robert Davis, Lawrence Wennogle, Peng Li, Gretchen Snyder, Joseph Hendrick, Allen Fienberg, Cedric O’Gorman, Sharon Mates

T48. Personal Experiences With the Digital Medicine System – A Case Series
Sonal Batra*, Rutgers Robert Wood Johnson Medical School
Ross Baker, Lada Markovtsova, Akshay Vashist, Praveen Raja, Timothy Peters-Strickland

T49. Subgroup Analyses of Baseline Characteristics and Treatment Response to Lisdexamfetamine vs. Placebo in Adults With Binge Eating Disorder
Susan Kornstein*, Virginia Commonwealth University
Caleb Bliss, Judith Kando, Manisha Madhoo

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
T50. Glucose Metabolism and Brain Bioenergetics Measured by 31P Magnetic Resonance Spectroscopy in Unaffected Siblings of Patients With Psychotic Disorders
Virginie-Anne Chouinard*, Harvard Medical School, McLean Hospital
Fei Du, Sang-Young Kim, Chiara Dalla Man, Claudio Cobelli, Aaron Cypess, Linda Valeri, Kyle Ryan, Guy Chouinard, David Henderson, Bruce Cohen, Dost Ongur

T51. Anti-Toxoplasma gondii IgM is Positively Correlated With Scores on the NIH Toolbox Flanker Inhibitory Control and Attention Test in Patients With Schizophrenia
Shiva Sharma*, University of Texas Harris County Psychiatric Center
Samy Abdullah, Robert Yolken, Olaoluwa Okusaga

T52. Audio vs. Audio-Video Recording as a Quality Measure in Schizophrenia Clinical Trials
David Daniel*, Bracket Global, LLC
Alan Kott

Faith DiBiasi*, Otsuka Pharmaceutical Development & Commercialization
Martha Sajatovic, Susan Legacy, Matthew Byerly, Christoph Correll, John Kane, Heather Fitzgerald, Ruth Ross

T54. Off-Hours Use of a Smartphone Application in Patients With Schizophrenia Spectrum Disorders Following Hospital Discharge
Eric Achtyes*, Michigan State University College of Human Medicine
Dror Ben-Zeev, Zhehui Luo, Heather Mayle, Roshanah Dayton, Brandi Burke, Armando Rotondi, Jennifer Gottlieb, Mary Brunette, Kim Mueser, Susan Gingerich, Piper Meyer-Kalos, Patricia Marcy, Nina Schooler, Delbert Robinson, John Kane

T55. Should Antipsychotic Medications for Schizophrenia be Given for a Lifetime? A Naturalistic Follow-Up Study
Ira Glick*, Stanford University School of Medicine

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
T56. Prognosis of Patients With Schizophrenia Treated With Antipsychotic Combinations: A Secondary Analysis of PROACTIVE Data
Adriana Foster*, Florida International University
Peter F. Buckley, John Lauriello, Stephen Looney, Nina Schooler

T57. Effects of Once-Daily Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 3 Study Data
Cherian Verghese*, Keystone Clinical Studies, LLC
Roger S. McIntyre, Joshua Burke, Hadley Le, Clinton Wright, Grace S. Liang

T58. Results of a Double-Blind, Placebo-Controlled, Tolerability Study of KarXT: A Novel Combination Targeting Muscarinic Acetylcholine Receptors Using Xanomeline With Trospium Chloride to Mitigate Cholinergic Side Effects
Stephen Brannan*, Karuna
Richard Kavoussi, Andrew Miller, Alan Breier

T59. Mean Square Successive Difference as a Marker of Data Quality in Schizophrenia Trials - Exploratory Analysis
Alan Kott*, Bracket
Xingmei Wang, Gary Sachs, David Daniel

T60. PANSS and CGI-S: 10-Years Later a Further Examination of Their Relationship
Janet Williams*, MedAvante
Selam Negash, Barbara Echevarria, Lisa Stein, Elisabeth Prochnik, Michael Ropacki

T61. Population Pharmacokinetic Analysis and Simulations of a 2-Month Regimen for Aripiprazole Lauroxil
Marjie Hard*, Alkermes, Inc.
Richard Mills, Brian Sadler, Lisa von Moltke

T62. Safety and Tolerability of 4, 6 and 8 Week Dose Intervals of Long-Acting Aripiprazole Lauroxil
Peter Weiden*, Alkermes, Inc.
Marjie Hard, Robert Ringer, Yangchun Du, David Walling, Chih-Chin Liu, Morteza Marandi

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
T63. Long-Term Safety of Aripiprazole Lauroxil for Maintenance Treatment of Schizophrenia
Ralph Aquila*, Fountain House
Henry Nasrallah, Robert Risinger, Arielle Stanford, Yangchun Du, Chih-Chin Liu, Peter Weiden

T64. Evaluation of the Potential for Valbenazine to Elicit Drug Interactions
Gordon Loewen*, Neurocrine Biosciences, Inc.
Rosa Luo, Evan Smith, Grace S. Liang, Haig Bozigian, Christopher O’Brien

T65. Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses From the Reconnect Study
Anita Clayton*, University of Virginia
Sheryl Kingsberg, James Simon, Robert Jordan, Johna Lucas

T66. A Phase 2, Double-Blind, Placebo-Controlled Study of SAGE-547 Injection in the Treatment of Severe Postpartum Depression
Stephen Kanes*, Sage Therapeutics
Helen Colquhoun, Handan Gunduz-Bruce, Shane Raines, Ryan Arnold, Amy Schacterle, James Doherty, C. Neill Epperson, Kristina Deligiannidis, Robert Riesenber, Ethan Hoffmann, Jeffrey Jonas, Samantha Meltzer-Brody

T67. Double-Blind, Randomized, Placebo-Controlled Study of Immediate-Release Viloxazine (SPN-812 IR) as a Novel Non-Stimulant Therapy in Adults With Attention-Deficit/Hyperactivity Disorder
Janet Johnson*, Supernus Pharmaceuticals, Inc.
Keith Saylor, Gabriela Tulloch, Tesfaye Lirano, Scott Brittain

T68. An Updated Genetic Model for Clozapine Response
Eric Huang*, Neurogenetics Section, Campbell Family Research Institute, Centre for Addiction and Mental Health
Clement Zai, Vanessa Goncalves, Arun Tiwari, James Kennedy

T69. Using Artificial Intelligence Platforms to Monitor and Identify Early Nonadherence Activity Based on Visual Confirmation of Medication Ingestion
Adam Hanina*, AiCure
Laura Shafner, Maggie McCue, Anne Rubin, Xinxin Dong, Elizabeth Hanson, Atul Mahabaleshwarkar, Thomas Macek

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
T70. Dasotraline in Children With Attention-Deficit/Hyperactivity Disorder: Results of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study
Robert Goldman*, Sunovion
Lenard Adler, Thomas Spencer, Robert Findling, Seth Hopkins, Kenneth Koblan, Kaushik Sarma, Xiaohai Wan, Antony Loebel

T71. Efficacy and Safety of Lurasidone in Children and Adolescent Patients With Bipolar I Depression
Robert Goldman*, Sunovion
Melissa DelBello, Debra Phillips, Ling Deng, Josephine Cucchiaro, Antony Loebel

T72. Short and Long-Term Effects of LPS on Behavior and Oxidative Stress in Male and Female C57bl/6 Mice
Caitlin Millett*, Penn State Milton S. Hershey Medical Center
Shannon Kelleher, Erika Saunders

T73. Is Parity a Protective Factor Against Suicide Attempts in Women Who Have Experienced Sexual Violence?
Victoria Valdez*, Kennedy University Hospital- Catholic University
Pablo Dueñas, Joyce Jimenez

T74. Adult Glucocorticoid Receptor mRNA in Response to an Acute Stressor: Role of CSF Corticotropin-Releasing Factor in HPA Axis Regulation Following Early Life Stress
Shariful Syed*, University of Miami
Jeremy Coplan

= New Investigator Awardee  = Pharmaceutical Pipeline Presentation
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaronson, Scott</td>
<td>19</td>
</tr>
<tr>
<td>Abdullah, Samy</td>
<td>93</td>
</tr>
<tr>
<td>Abraham, Eleenor</td>
<td>80</td>
</tr>
<tr>
<td>Abt, Markus</td>
<td>84</td>
</tr>
<tr>
<td>Achtyes, Eric</td>
<td>93</td>
</tr>
<tr>
<td>Adewole, Toyin</td>
<td>43, 75, 88</td>
</tr>
<tr>
<td>Adler, Lenard</td>
<td>96</td>
</tr>
<tr>
<td>Affinito, John</td>
<td>81, 84</td>
</tr>
<tr>
<td>Ahmad, Ayesha</td>
<td>79</td>
</tr>
<tr>
<td>Ahmad, Mohammed</td>
<td>19</td>
</tr>
<tr>
<td>Alam, Shaheen</td>
<td>86</td>
</tr>
<tr>
<td>Ali, Sanjida</td>
<td>90</td>
</tr>
<tr>
<td>Alpert, Jonathan</td>
<td>35</td>
</tr>
<tr>
<td>Althof, Stanley</td>
<td>84</td>
</tr>
<tr>
<td>Amara, Susan</td>
<td>92</td>
</tr>
<tr>
<td>Amatniek, Joan</td>
<td>77, 87, 88</td>
</tr>
<tr>
<td>Amerman, Paula</td>
<td>82</td>
</tr>
<tr>
<td>Anderson, Colleen</td>
<td>75, 86</td>
</tr>
<tr>
<td>Anderson, Jeffery</td>
<td>89</td>
</tr>
<tr>
<td>Andrade, Nadja</td>
<td>87</td>
</tr>
<tr>
<td>Andreezza, Ana</td>
<td>80</td>
</tr>
<tr>
<td>Anfray, Caroline</td>
<td>80, 89</td>
</tr>
<tr>
<td>Angelotta, Cara</td>
<td>67</td>
</tr>
<tr>
<td>Ansah, Kofi</td>
<td>57</td>
</tr>
<tr>
<td>Aquila, Ralph</td>
<td>95</td>
</tr>
<tr>
<td>Arango, Colso</td>
<td>88</td>
</tr>
<tr>
<td>Archibald, Abigail</td>
<td>77</td>
</tr>
<tr>
<td>Arnold, Ryan</td>
<td>95</td>
</tr>
<tr>
<td>Arnold, Valerie</td>
<td>86</td>
</tr>
<tr>
<td>Atkins, Alexandra</td>
<td>45, 78</td>
</tr>
<tr>
<td>Atsou, Kokuvi</td>
<td>81</td>
</tr>
<tr>
<td>Attiullah, Naureen</td>
<td>78</td>
</tr>
<tr>
<td>Badgett, Lynn</td>
<td>88</td>
</tr>
<tr>
<td>Bagot, Rosemary</td>
<td>76</td>
</tr>
<tr>
<td>Baker, Ross</td>
<td>18, 81, 82, 90, 92</td>
</tr>
<tr>
<td>Barabássy, Ágota</td>
<td>82</td>
</tr>
<tr>
<td>Barbier, Estelle</td>
<td>87</td>
</tr>
<tr>
<td>Barrett, Marna</td>
<td>91</td>
</tr>
<tr>
<td>Batra, Sonal</td>
<td>92</td>
</tr>
<tr>
<td>Bauer, Isabelle</td>
<td>19</td>
</tr>
<tr>
<td>Belchior, Patricia</td>
<td>72</td>
</tr>
<tr>
<td>Bender, William</td>
<td>57, 88</td>
</tr>
<tr>
<td>Bennett, Jeffrey</td>
<td>85</td>
</tr>
<tr>
<td>Ben-Zeev, Dror</td>
<td>93</td>
</tr>
<tr>
<td>Berrett, Jessica</td>
<td>89</td>
</tr>
<tr>
<td>Bertzos, Kristina</td>
<td>90</td>
</tr>
<tr>
<td>Bhide, Pradeep</td>
<td>75</td>
</tr>
<tr>
<td>Biederman, Joseph</td>
<td>75, 86</td>
</tr>
<tr>
<td>Birur, Badari</td>
<td>56</td>
</tr>
<tr>
<td>Bishnoi, Ram</td>
<td>19</td>
</tr>
<tr>
<td>Bixler, Edward</td>
<td>75</td>
</tr>
<tr>
<td>Black, Sandra</td>
<td>80</td>
</tr>
<tr>
<td>Bliss, Caleb</td>
<td>92</td>
</tr>
<tr>
<td>Boerescu, Daniela</td>
<td>78</td>
</tr>
<tr>
<td>Bold, Krysten</td>
<td>76</td>
</tr>
<tr>
<td>Bougie, Joanna</td>
<td>80</td>
</tr>
<tr>
<td>Bouhlal, Sofia</td>
<td>7, 76</td>
</tr>
<tr>
<td>Bozigian, Haig</td>
<td>83, 95</td>
</tr>
<tr>
<td>Brady, Chris</td>
<td>90</td>
</tr>
<tr>
<td>Brannan, Stephen</td>
<td>42, 94</td>
</tr>
<tr>
<td>Breier, Alan</td>
<td>94</td>
</tr>
<tr>
<td>Brenner, Helena</td>
<td>79</td>
</tr>
<tr>
<td>Brent, Benjamin</td>
<td>79</td>
</tr>
<tr>
<td>Brewer, Claudette</td>
<td>82, 92</td>
</tr>
<tr>
<td>Brignone, Melanie</td>
<td>81</td>
</tr>
<tr>
<td>Brique, Benjamin</td>
<td>81</td>
</tr>
<tr>
<td>Brissette, Suzanne</td>
<td>89</td>
</tr>
<tr>
<td>Brittain, Scott</td>
<td>75, 88, 95</td>
</tr>
<tr>
<td>Brookhart, Alan</td>
<td>78</td>
</tr>
<tr>
<td>Brown, Delisa</td>
<td>79</td>
</tr>
<tr>
<td>Brown, Hannah</td>
<td>79</td>
</tr>
<tr>
<td>Brownstein, Michael</td>
<td>85</td>
</tr>
<tr>
<td>Brueckner, Eric</td>
<td>81</td>
</tr>
<tr>
<td>Bruneau, Julie</td>
<td>89</td>
</tr>
<tr>
<td>Brunette, Mary</td>
<td>93</td>
</tr>
<tr>
<td>Buckley, Peter F.</td>
<td>94</td>
</tr>
<tr>
<td>Budman, Cathy</td>
<td>89</td>
</tr>
<tr>
<td>Burcu, Mehmet</td>
<td>7, 81</td>
</tr>
<tr>
<td>Burger, Francisco</td>
<td>85</td>
</tr>
<tr>
<td>Burke, Brandi</td>
<td>93</td>
</tr>
<tr>
<td>Burke, Joshua</td>
<td>94</td>
</tr>
<tr>
<td>Burke, Shanna L.</td>
<td>7, 46</td>
</tr>
<tr>
<td>Bushnell, Greta</td>
<td>78</td>
</tr>
<tr>
<td>Busner, Joan</td>
<td>79</td>
</tr>
<tr>
<td>Byerly, Matthew</td>
<td>77, 93</td>
</tr>
<tr>
<td>Caceda, Ricardo</td>
<td>80</td>
</tr>
<tr>
<td>Cahill, Michael</td>
<td>76</td>
</tr>
<tr>
<td>Calabrese, Joseph</td>
<td>22, 77, 87, 88</td>
</tr>
<tr>
<td>Calderaro, Marco Antonio</td>
<td>7, 44</td>
</tr>
<tr>
<td>Calipari, Erin</td>
<td>76</td>
</tr>
<tr>
<td>Camprodon, Joan</td>
<td>54</td>
</tr>
<tr>
<td>Canning, Jacquelyn</td>
<td>81</td>
</tr>
<tr>
<td>Carpenter, David</td>
<td>89</td>
</tr>
<tr>
<td>Carson, Richard</td>
<td>83</td>
</tr>
<tr>
<td>Carson, William H.</td>
<td>77, 87, 88</td>
</tr>
</tbody>
</table>
Author Index

Carter, Sierra 87
Cassano, Paolo 73
Cates, Hannah 76
Cather, Corinne 79
Cena, Frances 84
Chandran, Prakash 80
Chang, Cheng-Tao 80, 82, 83
Chang, Lee 79
Charney, Dennis 87
Charriez, Christina 89
Chelminski, Ivona 88
Chen, Alexander 84
Chen, Changzheng 80
Cheng, Laura 84
Cheung, Joey 77
Chi-Burris, Kathy 82
Chitayat, David 84
Chokka, Pratap 80
Chouinard, Guy 93
Chouinard, Virginie-Anne 7, 53, 93
Chow, Shein 76
Christensen, Michael Cronquist 76
Chronis-Tuscano, Andrea 86
Citrome, Leslie 19, 22, 60, 82
Clark, Crystal 19, 44, 67
Clark, Janet 92
Clayton, Anita 19, 42, 95
Cobelli, Claudio 93
Coccaro, Emil F. 6, 53
Coffey, Alissa 75
Coffey, Barbara 89
Cohen, Bruce 93
Cohen, Elan 82
Cohen, Lawrence 19
Cohen, Lee 39, 84
Collins, Katherine 87
Colquhoun, Helen 78, 95
Compton, Michael T. 10, 64
Compton, Scott 78
Coplan, Jeremy 96
Correll, Christoph U. 19, 21, 22, 77, 82, 83, 88, 90, 93
Costi, Sara 87
Cox, Kevin 77, 87, 88
Cread, Rebecca 89
Creatura, Gina 83
Crismon, Lynn 19
Crockett, R. Steve 76
Cruz, Stephanie 79
Cucchiara, Andrew 91
Cucchiara, Josephine 88, 96
Cummings, Jeffrey 80
Cusin, Cristina 79
Cutler, Andrew 55
Cypress, Aaron 93
Dale, Chelsea 77
Dalrymple, Kristy 88
Danchenko, Natalya 81
Dang, Jonathan 58
Daniel, David 83, 93, 94
Darpo, Borje 76
Davari, Maryam 85, 90
Davis, Lori 18, 21, 56
Davis, Michael 29, 66, 81
Davis, Robert 79, 92
Dayton, Roshanah 93
Debattista, Charles 79
DeFrancisco, Don 88
DelBello, Melissa 96
Delgado, Pedro 80
Deligiannidis, Kristina 22, 95
Demos, George 82
Deng, Ling 88, 96
DeRogatis, Leonard 84
DeSousa, Norberto 86
Detke, Michael 72, 73
Diamond, Françoise 81
DiBiasi, Faith 77, 93
DiClemente, Guillermo 85
DiPetrillo, Lauren 83
Djan, Joseph 89
Doherty, James 78, 95
Donahue, Lauren 79
Dong, Xinxin 84, 95
Donovan, Abigail 79
D’Souza, Deepak 83
Du, Fei 93
Du, Yangchun 94, 95
Dubitsky, Greg 81
Dubreucq, Simon 89
Dueñas, Pablo 96
Durgam, Suresh 80, 83
Dusetzina, Stacie 78
Eack, Shaun 37
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earley, Willie</td>
<td>82, 83</td>
</tr>
<tr>
<td>Echevarria, Barbara</td>
<td>94</td>
</tr>
<tr>
<td>Edelen, Maria</td>
<td>39</td>
</tr>
<tr>
<td>Edwards, John</td>
<td>80</td>
</tr>
<tr>
<td>Ehlich, Elliot</td>
<td>18, 35</td>
</tr>
<tr>
<td>El Hage, Cynthia</td>
<td>89</td>
</tr>
<tr>
<td>Elia, Josephine</td>
<td>75</td>
</tr>
<tr>
<td>Elias, Pamela</td>
<td>79</td>
</tr>
<tr>
<td>Ellingrod, Vicki</td>
<td>83</td>
</tr>
<tr>
<td>Engel, Christopher</td>
<td>90</td>
</tr>
<tr>
<td>Engelhardt, Nina</td>
<td>85</td>
</tr>
<tr>
<td>Engels, Jean</td>
<td>87</td>
</tr>
<tr>
<td>Epperson, C. Neill</td>
<td>95</td>
</tr>
<tr>
<td>Epstein, Irvin</td>
<td>71</td>
</tr>
<tr>
<td>Eramo, Anna</td>
<td>81</td>
</tr>
<tr>
<td>Ereshefsky, Larry</td>
<td>81</td>
</tr>
<tr>
<td>Falk, Daniel</td>
<td>38, 39</td>
</tr>
<tr>
<td>Faroone, Stephen</td>
<td>75</td>
</tr>
<tr>
<td>Farchione, Tiffany</td>
<td>8, 16, 18, 19, 21, 29, 52, 66, 74</td>
</tr>
<tr>
<td>Farokhnia, Mehdi</td>
<td>76</td>
</tr>
<tr>
<td>Fava, Maurizio</td>
<td>19, 22, 35, 41, 43, 54, 77, 79, 91</td>
</tr>
<tr>
<td>Feder, Adriano</td>
<td>87</td>
</tr>
<tr>
<td>Feldman, Clifford</td>
<td>88</td>
</tr>
<tr>
<td>Felger, Jennifer</td>
<td>37</td>
</tr>
<tr>
<td>Feng, Lei</td>
<td>89</td>
</tr>
<tr>
<td>Fienberg, Allen</td>
<td>92</td>
</tr>
<tr>
<td>Figueroa, Janet</td>
<td>77</td>
</tr>
<tr>
<td>Findling, Robert</td>
<td>75, 86, 96</td>
</tr>
<tr>
<td>Finnema, Sjoerd</td>
<td>83</td>
</tr>
<tr>
<td>Fischer, Bernard</td>
<td>66, 81</td>
</tr>
<tr>
<td>Fisher, Dennis</td>
<td>76</td>
</tr>
<tr>
<td>Fitts, David</td>
<td>75, 86</td>
</tr>
<tr>
<td>Fitzgerald, Heather</td>
<td>77, 93</td>
</tr>
<tr>
<td>Fitzgerald, Maura</td>
<td>75</td>
</tr>
<tr>
<td>Florea, Ioana</td>
<td>76</td>
</tr>
<tr>
<td>Flynn, Martina</td>
<td>79</td>
</tr>
<tr>
<td>Forsellius-Bielen, Kimberlee</td>
<td>83</td>
</tr>
<tr>
<td>Foster, Adriana</td>
<td>94</td>
</tr>
<tr>
<td>Foster, Simmie</td>
<td>7, 35, 77</td>
</tr>
<tr>
<td>Foulds, Jonathan</td>
<td>79</td>
</tr>
<tr>
<td>Fox, Jason</td>
<td>90</td>
</tr>
<tr>
<td>François, Clément</td>
<td>81</td>
</tr>
<tr>
<td>Fraser, Heather</td>
<td>85</td>
</tr>
<tr>
<td>Freeman, Marlene</td>
<td>17, 22, 39, 40, 63, 79, 84</td>
</tr>
<tr>
<td>French, William</td>
<td>75, 86</td>
</tr>
<tr>
<td>Freudenreich, Oliver</td>
<td>79</td>
</tr>
<tr>
<td>Friedman, Michael</td>
<td>78</td>
</tr>
<tr>
<td>Frye, Mark</td>
<td>91</td>
</tr>
<tr>
<td>Fucito, Lisa</td>
<td>76</td>
</tr>
<tr>
<td>Galling, Britta</td>
<td>90</td>
</tr>
<tr>
<td>Gandhi, Kriti</td>
<td>91</td>
</tr>
<tr>
<td>Gaynes, Bradley</td>
<td>19, 46, 78</td>
</tr>
<tr>
<td>Gelenberg, Alan</td>
<td>17, 18, 22, 23, 36, 91</td>
</tr>
<tr>
<td>Gelinas, Isabelle</td>
<td>72</td>
</tr>
<tr>
<td>Gendreau, Judith</td>
<td>87</td>
</tr>
<tr>
<td>Gendreau, Michael</td>
<td>87</td>
</tr>
<tr>
<td>Geoffroy, Pierre</td>
<td>55, 76</td>
</tr>
<tr>
<td>Ghabrash, Maykel</td>
<td>89</td>
</tr>
<tr>
<td>Giddens, Jennifer M.</td>
<td>82, 92</td>
</tr>
<tr>
<td>Gift, Thomas</td>
<td>75</td>
</tr>
<tr>
<td>Gingerich, Susan</td>
<td>93</td>
</tr>
<tr>
<td>Giroudet, Christelle</td>
<td>72, 80, 89</td>
</tr>
<tr>
<td>Glick, Ira</td>
<td>60, 67, 82, 93</td>
</tr>
<tr>
<td>Goldberg, Joseph</td>
<td>22, 54</td>
</tr>
<tr>
<td>Goldman, Robert</td>
<td>88, 96</td>
</tr>
<tr>
<td>Gold, Philip</td>
<td>91</td>
</tr>
<tr>
<td>Goldsmith, Paul</td>
<td>84</td>
</tr>
<tr>
<td>Gommoll, Carl</td>
<td>80</td>
</tr>
<tr>
<td>Goncalves, Vanessa</td>
<td>95</td>
</tr>
<tr>
<td>Gooneratne, Nalaka</td>
<td>91</td>
</tr>
<tr>
<td>Gopinath, Srinath</td>
<td>7, 84</td>
</tr>
<tr>
<td>Gordon, Jesh</td>
<td>14, 64</td>
</tr>
<tr>
<td>Gorlin, Eugenia</td>
<td>88</td>
</tr>
<tr>
<td>Gottlieb, Jennifer</td>
<td>93</td>
</tr>
<tr>
<td>Greaney, Jody</td>
<td>90</td>
</tr>
<tr>
<td>Grosz, Daniel</td>
<td>88</td>
</tr>
<tr>
<td>Gueorguieva, Ralitza</td>
<td>76</td>
</tr>
<tr>
<td>Guillon, Christophe</td>
<td>85</td>
</tr>
<tr>
<td>Gunduz-Bruce, Handan</td>
<td>95</td>
</tr>
<tr>
<td>Guo, Hua</td>
<td>83</td>
</tr>
<tr>
<td>Guzman, Michele</td>
<td>59</td>
</tr>
<tr>
<td>Hack, Laura M.</td>
<td>7, 87</td>
</tr>
<tr>
<td>Hakonarson, Hakon</td>
<td>75</td>
</tr>
<tr>
<td>Hameed, Ahmad</td>
<td>19, 79, 91</td>
</tr>
<tr>
<td>Hameed, Usman</td>
<td>19, 45, 79</td>
</tr>
<tr>
<td>Hanina, Adam</td>
<td>84, 95</td>
</tr>
<tr>
<td>Hanson, Elizabeth</td>
<td>84, 95</td>
</tr>
<tr>
<td>Hard, Marjie</td>
<td>94</td>
</tr>
<tr>
<td>Haroon, Ebrahim</td>
<td>19</td>
</tr>
<tr>
<td>Harvey, Philip</td>
<td>78</td>
</tr>
<tr>
<td>Hassman, Howard</td>
<td>82</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------</td>
</tr>
<tr>
<td>Hefting, Nanco</td>
<td>81</td>
</tr>
<tr>
<td>Heilig, Markus</td>
<td>87</td>
</tr>
<tr>
<td>Heindel, Ned</td>
<td>85</td>
</tr>
<tr>
<td>Henderson, David</td>
<td>93</td>
</tr>
<tr>
<td>Hendrick, Joseph</td>
<td>92</td>
</tr>
<tr>
<td>Henningfield, Jack</td>
<td>55</td>
</tr>
<tr>
<td>Henry, Melissia</td>
<td>88</td>
</tr>
<tr>
<td>Henry, Michael</td>
<td>20, 54</td>
</tr>
<tr>
<td>Hernandez-Diaz, Sonia</td>
<td>84</td>
</tr>
<tr>
<td>Herrmann, Nathan</td>
<td>80</td>
</tr>
<tr>
<td>Hertel, Peter</td>
<td>77, 87, 88</td>
</tr>
<tr>
<td>Hester, Shelly</td>
<td>92</td>
</tr>
<tr>
<td>Hobart, Mary</td>
<td>81, 90, 91</td>
</tr>
<tr>
<td>Hodes, Georgia</td>
<td>76</td>
</tr>
<tr>
<td>Hoepnner, Bettina</td>
<td>79</td>
</tr>
<tr>
<td>Hoffmann, Ethan</td>
<td>78, 95</td>
</tr>
<tr>
<td>Holt, Daphne</td>
<td>79</td>
</tr>
<tr>
<td>Hopkins, Seth</td>
<td>96</td>
</tr>
<tr>
<td>Horn, Sarah</td>
<td>87</td>
</tr>
<tr>
<td>Hossain, Shawn</td>
<td>82</td>
</tr>
<tr>
<td>Howes, John</td>
<td>76</td>
</tr>
<tr>
<td>Huang, Eric</td>
<td>95</td>
</tr>
<tr>
<td>Huang, Yingying</td>
<td>73</td>
</tr>
<tr>
<td>Huybrechts, Krista</td>
<td>67</td>
</tr>
<tr>
<td>Incledon, Bev</td>
<td>86</td>
</tr>
<tr>
<td>Ionescu, Dawn</td>
<td>77, 79</td>
</tr>
<tr>
<td>Iosifescu, Dan</td>
<td>73, 79, 87</td>
</tr>
<tr>
<td>Irwin, Kelly</td>
<td>79</td>
</tr>
<tr>
<td>IsHak, Waguih</td>
<td>58</td>
</tr>
<tr>
<td>Jacobsen, Paula</td>
<td>81, 91</td>
</tr>
<tr>
<td>Jacobson, William</td>
<td>80, 91</td>
</tr>
<tr>
<td>Jaeger, Judith</td>
<td>91</td>
</tr>
<tr>
<td>James, Andrew</td>
<td>80</td>
</tr>
<tr>
<td>James, Prisciandaro</td>
<td>79, 81</td>
</tr>
<tr>
<td>Jankovic, Joseph</td>
<td>89</td>
</tr>
<tr>
<td>Jattlow, Peter</td>
<td>76</td>
</tr>
<tr>
<td>Jha, Manish</td>
<td>59, 79</td>
</tr>
<tr>
<td>Jiang, Ying</td>
<td>83</td>
</tr>
<tr>
<td>Jimenez, Daniel</td>
<td>30</td>
</tr>
<tr>
<td>Jimenez, Joyce</td>
<td>96</td>
</tr>
<tr>
<td>Jimenez-Shahed, Joohi</td>
<td>89</td>
</tr>
<tr>
<td>Jin, Na</td>
<td>77, 87, 88, 90</td>
</tr>
<tr>
<td>Johe, Karl</td>
<td>41</td>
</tr>
<tr>
<td>John, Harrison</td>
<td>78</td>
</tr>
<tr>
<td>Johnson, Brian</td>
<td>77, 87, 88</td>
</tr>
<tr>
<td>Johnson, Janet</td>
<td>75, 88, 95</td>
</tr>
<tr>
<td>Johnstone, Andrea</td>
<td>87</td>
</tr>
<tr>
<td>Jonas, Jeffrey</td>
<td>95</td>
</tr>
<tr>
<td>Jordan, Ayana</td>
<td>7, 76</td>
</tr>
<tr>
<td>Jordan, Robert</td>
<td>84, 95</td>
</tr>
<tr>
<td>Joseph, Ashok</td>
<td>82</td>
</tr>
<tr>
<td>Jovanovic, Tanja</td>
<td>87</td>
</tr>
<tr>
<td>Judge, Heidi</td>
<td>79</td>
</tr>
<tr>
<td>Jutras-Aswad, Didier</td>
<td>89</td>
</tr>
<tr>
<td>Kadriu, Bashkim</td>
<td>7, 91</td>
</tr>
<tr>
<td>Kando, Judith</td>
<td>92</td>
</tr>
<tr>
<td>Kane, John</td>
<td>22, 37, 59, 77, 82, 93</td>
</tr>
<tr>
<td>Kanes, Stephen</td>
<td>41, 42, 78, 95</td>
</tr>
<tr>
<td>Katzelnick, David</td>
<td>36</td>
</tr>
<tr>
<td>Katzman, Martin</td>
<td>71</td>
</tr>
<tr>
<td>Kavoussi, Richard</td>
<td>94</td>
</tr>
<tr>
<td>Keck, Paul</td>
<td>36</td>
</tr>
<tr>
<td>Keefe, Richard</td>
<td>20, 45, 78, 91</td>
</tr>
<tr>
<td>Kelleher, Shannon</td>
<td>96</td>
</tr>
<tr>
<td>Kennedy, James</td>
<td>95</td>
</tr>
<tr>
<td>Khan, Anzalee</td>
<td>78</td>
</tr>
<tr>
<td>Khan, Arifulla</td>
<td>22, 80, 85</td>
</tr>
<tr>
<td>Khan, Munir</td>
<td>75</td>
</tr>
<tr>
<td>Kiedrow, Keith</td>
<td>57</td>
</tr>
<tr>
<td>Kitts, Clint</td>
<td>80</td>
</tr>
<tr>
<td>Kim, Celia</td>
<td>75</td>
</tr>
<tr>
<td>Kim, Jean</td>
<td>66, 81</td>
</tr>
<tr>
<td>Kim, Sang-Young</td>
<td>93</td>
</tr>
<tr>
<td>Kim, Soo-Jeong</td>
<td>75</td>
</tr>
<tr>
<td>Kinch, Russell</td>
<td>84</td>
</tr>
<tr>
<td>Kingsberg, Sheryl</td>
<td>95</td>
</tr>
<tr>
<td>Kinon, Bruce</td>
<td>21, 29</td>
</tr>
<tr>
<td>Kiss, Alex</td>
<td>80</td>
</tr>
<tr>
<td>Klassen, Larry</td>
<td>71</td>
</tr>
<tr>
<td>Ko, Mancia</td>
<td>92</td>
</tr>
<tr>
<td>Koblan, Kenneth</td>
<td>86, 96</td>
</tr>
<tr>
<td>Kolla, Bhanu Prakash</td>
<td>7, 44</td>
</tr>
<tr>
<td>Kong, Lan</td>
<td>75</td>
</tr>
<tr>
<td>Koola, Maju</td>
<td>87</td>
</tr>
<tr>
<td>Kopelowicz, Alex</td>
<td>92</td>
</tr>
<tr>
<td>Kornstein, Susan</td>
<td>20, 92</td>
</tr>
<tr>
<td>Kott, Alan</td>
<td>79, 93, 94</td>
</tr>
<tr>
<td>Kramer, Ken</td>
<td>80, 90</td>
</tr>
<tr>
<td>Kramer, William</td>
<td>76</td>
</tr>
<tr>
<td>Krishnamurthy, Venkatesh</td>
<td>75</td>
</tr>
<tr>
<td>Kugel, Marla</td>
<td>90</td>
</tr>
<tr>
<td>Kupfer, David J.</td>
<td>5, 18, 53</td>
</tr>
<tr>
<td>Lam, Vincent</td>
<td>76</td>
</tr>
<tr>
<td>Lanctôt, Krista</td>
<td>80</td>
</tr>
<tr>
<td>Landsman-Blumberg, Pamela</td>
<td>90</td>
</tr>
</tbody>
</table>
Author Index

Lardner, Casey 76
Laszlovszky, István 83
Lauriello, John 94
Lawson, Erica 82, 92
Le, Hadley 94
Lederman, Seth 87
Lee, Mary 76
Lee, Tong 76
Legacy, Susan 77, 93
Leggio, Lorenzo 76
Leslie, Douglas 75
Lespérance, François 89
Lespérance, Paul 89
Lewis-Fernández, Roberto 10, 63
Li, Peng 79, 92
Liang, Grace S. 83, 94, 95
Libowitz, Michael 85
Lindenmayer, Jean-Pierre 59, 60
Liranso, Tesfaye 75, 95
Lisanby, Sarah 65
Lisotto, Maria 20
Litten, Raye 12, 18, 64
Liu, Chih-Chin 94, 95
Loebel, Antony 18, 86, 88, 96
Loewen, Gordon 83, 95
Loft, Henrik 76
Looney, Stephen 94
Lu, Kaifeng 83
Lu, Shi-fang 85
Luca, Gianina 85
Lucas, Johna 84, 95
Luckenbaugh, David 91
Luo, Rosa 83, 95
Luo, Zhehui 93
Macek, Thomas A. 43, 84, 95
Machado-Vieira, Rodrigo 31, 91
Machlovi, Saima 76
MacLaurin, Sarah 79
Macri, Ben 79
Madhoo, Manisha 92
Mahabaleshwar, Atul 81, 84, 95
Majd, Marzieh 90
Man, Chiara Dalla 93
Mantua, Valentina 9, 16, 52, 74
Marandi, Morteza 94
Marchant, Barrie 75
March, Mary 90
Marcus, Ronald 35, 85
Marcy, Patricia 93
Marder, Stephen 18, 20, 22
Mariano, Tim 20
Marin, Marie-France 86
Marino, Jehan 90
Markovtsova, Lada 92
Marraffino, Andrea 86
Marsh, Julie 72
Mastoudlis, Angela 92
Mates, Sharon 79, 92
Mathé, Aleksander 87
Mathew, Sanjay 79, 84
Mathew, Shiny 66
Mathis, Mitchell 40
Matta, Andy 66, 81
Mau, Marin 87
Mayle, Heather 93
Mazzotti, Diego 75
McCacken, Courtney 77
McCue, Maggie 81, 84, 95
McDonnell, David 83
McDougle, Christopher 77
McGlade, Erin 92
McGurk, Dennis 16, 65
McIntyre, Roger S. 76, 94
McNamara, Cynthia 85
McNulty, Eileen 85
McQuade, Robert 77, 87, 88
Meltzer-Brody, Samantha 39, 78, 95
Merikle, Elizabeth 80
Meyer-Kalos, Piper 93
Meyer, Roger 75, 91
Migliore, Raffaele 80
Milad, Mohammed 86
Miller, Andrew 94
Miller, Brian 81
Miller, Lindsay 75, 86
Millet, Robert 89
Millett, Caitlin 96
Mills, Richard 94
Milovan, Denise 56
Milrod, Barbara 20
Mitchell, Michael 91
Moca, Marian 86
Montoya, Ivan 21
Moreno, Francisco 20, 30, 31
Morin, Lynn 21, 29, 41
Morrissey, Judy 88
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucha, Lisa</td>
<td>81</td>
</tr>
<tr>
<td>Mueser, Kim</td>
<td>93</td>
</tr>
<tr>
<td>Muniz, Javier</td>
<td>66</td>
</tr>
<tr>
<td>Murphy, Tanya</td>
<td>89</td>
</tr>
<tr>
<td>Murrough, James</td>
<td>43, 79, 87</td>
</tr>
<tr>
<td>Myers, Kimberly</td>
<td>82</td>
</tr>
<tr>
<td>Nabulsi, Nabeel</td>
<td>83</td>
</tr>
<tr>
<td>Nakamura, Richard K.</td>
<td>15, 64</td>
</tr>
<tr>
<td>Namey, Leah</td>
<td>79</td>
</tr>
<tr>
<td>Naovarat, Benjamin</td>
<td>82</td>
</tr>
<tr>
<td>Narasimhan, Meera</td>
<td>78</td>
</tr>
<tr>
<td>Nasrallah, Henry</td>
<td>83, 84, 95</td>
</tr>
<tr>
<td>Navia, Bradford</td>
<td>44</td>
</tr>
<tr>
<td>Negash, Selam</td>
<td>94</td>
</tr>
<tr>
<td>Neil, Garry</td>
<td>43, 86</td>
</tr>
<tr>
<td>Nelson, Craig</td>
<td>20</td>
</tr>
<tr>
<td>Németh, György</td>
<td>83</td>
</tr>
<tr>
<td>Nestler, Eric</td>
<td>76</td>
</tr>
<tr>
<td>Newcomer, John</td>
<td>17, 22</td>
</tr>
<tr>
<td>Newcorn, Jeffrey</td>
<td>86</td>
</tr>
<tr>
<td>Nierenberg, Andrew</td>
<td>11, 64</td>
</tr>
<tr>
<td>Nomikos, George</td>
<td>78, 81, 91</td>
</tr>
<tr>
<td>Norquist, Grayson</td>
<td>15, 65</td>
</tr>
<tr>
<td>Norrmholm, Seth</td>
<td>57</td>
</tr>
<tr>
<td>Norton, James</td>
<td>82</td>
</tr>
<tr>
<td>Nuechterlein, Keith</td>
<td>38</td>
</tr>
<tr>
<td>Nyilas, Margarettta</td>
<td>77, 82, 87, 88, 92</td>
</tr>
<tr>
<td>Nylander, Anna-Greta</td>
<td>91</td>
</tr>
<tr>
<td>Oakley, Margot</td>
<td>79</td>
</tr>
<tr>
<td>Oberbarnscheidt, Thersilla</td>
<td>85, 90</td>
</tr>
<tr>
<td>O’Brien, Christopher</td>
<td>83, 95</td>
</tr>
<tr>
<td>O’Gorman, Cedric</td>
<td>45, 92</td>
</tr>
<tr>
<td>Okusaga, Olaoluwa</td>
<td>82, 93</td>
</tr>
<tr>
<td>Olsson, Emily</td>
<td>7, 76</td>
</tr>
<tr>
<td>Olsen, Christina Kurre</td>
<td>80, 91</td>
</tr>
<tr>
<td>O’Malley, Stephanie</td>
<td>18, 38, 76</td>
</tr>
<tr>
<td>Ongur, Dost</td>
<td>93</td>
</tr>
<tr>
<td>Onwuameze, Obiora</td>
<td>85</td>
</tr>
<tr>
<td>Osokolir, Nader</td>
<td>88</td>
</tr>
<tr>
<td>Ouellet-Plamondon, Clairélaine</td>
<td>89</td>
</tr>
<tr>
<td>Paker, Asif</td>
<td>83</td>
</tr>
<tr>
<td>Palumbo, Joseph</td>
<td>18</td>
</tr>
<tr>
<td>Pani, Luca</td>
<td>9, 16, 18, 52, 74</td>
</tr>
<tr>
<td>Papadopoulos, Elektra</td>
<td>38</td>
</tr>
<tr>
<td>Papakostas, George</td>
<td>41, 79</td>
</tr>
<tr>
<td>Parides, Michael</td>
<td>87</td>
</tr>
<tr>
<td>Parikh, Sagar</td>
<td>81</td>
</tr>
<tr>
<td>Parsons, Jodi</td>
<td>89</td>
</tr>
<tr>
<td>Patel, Hiren</td>
<td>57</td>
</tr>
<tr>
<td>Patel, Mehul</td>
<td>83</td>
</tr>
<tr>
<td>Pathak, Sanjeev</td>
<td>83</td>
</tr>
<tr>
<td>Patkar, Ashwin</td>
<td>76, 89</td>
</tr>
<tr>
<td>Patterson, Tom</td>
<td>78</td>
</tr>
<tr>
<td>Pena, Catherine</td>
<td>76</td>
</tr>
<tr>
<td>Perera, Philip</td>
<td>89</td>
</tr>
<tr>
<td>Perez, Magdalena</td>
<td>72</td>
</tr>
<tr>
<td>Perez, Vanessa</td>
<td>80</td>
</tr>
<tr>
<td>Perry, Pamela</td>
<td>77, 88</td>
</tr>
<tr>
<td>Peters, Ashild</td>
<td>87</td>
</tr>
<tr>
<td>Peters, Perry</td>
<td>87</td>
</tr>
<tr>
<td>Peters-Strickland, Timothy</td>
<td>82, 92</td>
</tr>
<tr>
<td>Phillips, Debra</td>
<td>96</td>
</tr>
<tr>
<td>Phillips, Katharine</td>
<td>20, 21, 22</td>
</tr>
<tr>
<td>Pigott, Teresa</td>
<td>77</td>
</tr>
<tr>
<td>Pikalov, Andrei</td>
<td>86</td>
</tr>
<tr>
<td>Pliszka, Steven</td>
<td>86</td>
</tr>
<tr>
<td>Polimanti, Renato</td>
<td>45</td>
</tr>
<tr>
<td>Politte, Laura</td>
<td>7, 77</td>
</tr>
<tr>
<td>Pollack, Mark</td>
<td>65</td>
</tr>
<tr>
<td>Potkin, Steven</td>
<td>83</td>
</tr>
<tr>
<td>Potter, William</td>
<td>54</td>
</tr>
<tr>
<td>Prochnik, Elisabeth</td>
<td>94</td>
</tr>
<tr>
<td>Proulx, Jean</td>
<td>80</td>
</tr>
<tr>
<td>Puentes, Ruby Castilla</td>
<td>30</td>
</tr>
<tr>
<td>Purushothaman, Immanuel</td>
<td>76</td>
</tr>
<tr>
<td>Quirk, Mike</td>
<td>78</td>
</tr>
<tr>
<td>Rabinowitz, Jonathan</td>
<td>72</td>
</tr>
<tr>
<td>Radford, Philip</td>
<td>89</td>
</tr>
<tr>
<td>Radhakrishnan, Rajiv</td>
<td>7, 83</td>
</tr>
<tr>
<td>Raines, Shane</td>
<td>78, 95</td>
</tr>
<tr>
<td>Raison, Charles</td>
<td>86</td>
</tr>
<tr>
<td>Raja, Praveen</td>
<td>92</td>
</tr>
<tr>
<td>Rampakakis, Emmanueluil</td>
<td>80</td>
</tr>
<tr>
<td>Randolph, Christopher</td>
<td>78</td>
</tr>
<tr>
<td>Rapaport, Mark H.</td>
<td>17, 18, 22, 29, 37, 52, 64, 74</td>
</tr>
<tr>
<td>Rauch, Sheila</td>
<td>56</td>
</tr>
<tr>
<td>Reimherr, Frederick</td>
<td>75</td>
</tr>
<tr>
<td>Renshaw, Perry</td>
<td>92</td>
</tr>
<tr>
<td>Ressler, Kerry</td>
<td>77, 87</td>
</tr>
<tr>
<td>Revicki, Dennis</td>
<td>84</td>
</tr>
<tr>
<td>Riesenberg, Robert</td>
<td>95</td>
</tr>
<tr>
<td>Risinger, Robert</td>
<td>94, 95</td>
</tr>
<tr>
<td>Robichaud, A.J.</td>
<td>78</td>
</tr>
<tr>
<td>Robinson, Delbert</td>
<td>38, 82, 93</td>
</tr>
</tbody>
</table>
Author Index

Rodriquez, Carolyn 30
Roers, Erika 42, 88
Ropacki, Michael 94
Rosenberg, David 88
Ross, Ruth 77, 93
Rotolo, Renee 83
Rotondi, Armando 93
Roy, Marcela 79
Rubin, Anne 95
Rubinow, David 78
Rubio, Jose M. 7, 82
Ruckle, Jon 89
Rudorfer, Matthew 67
Rush, A. John 21, 29, 36
Russo, Scott 76
Ruthirakuhan, Myuri 80
Ryan, Kyle 93
Sachs, Gary 73, 94
Sadler, Brian 94
Salter, Daniel 81
Sajatovic, Martha 55, 77, 93
Saliu, Irma 82
Sallee, Floyd 86
Saltmarche, Anita 74
Saltz, Bruce 20
Salvadore, Giacomo 41
Salzman, Phyllis 77, 87, 88
Sanacora, Gerard 79
Sanchez, Raymond 77, 82, 87, 88, 92
Sankoh, Abdul 78
Sarampote, Christopher 17
Sarkey, Sara 81
Sarma, Kaushik 96
Sassler, Tyler 86
Saunders, Erika 20, 36, 90, 96
Savella, Gina 84
Saxby, Brian 78
Sayed, Sehrish 87
Saylor, Keith 95
Scafidi, Michael 79
Scahill, Lawrence 77
Schacterle, Amy 95
Schatzberg, Alan 79
Schneider, Andrea 58
Schoenfelder, Erin 86
Schooler, Nina R. 21, 29, 37, 54, 65, 82, 84, 93, 94
Schuster, Jen 81
Seo, Dongju 7, 46
Setnik, Beatrice 55
Shackelford, Theresa 89
Shafner, Laura 84, 95
Shari, Sutor 91
Sharma, Anup 7, 91
Sharma, Shiva 93
Sheehan, David 82, 92
Shelton, Richard 20, 37, 56
Sherman, Chelsea 80
Sheth, Chandni 92
Shonka, Sophia 75
Shprecher, David 89
Shram, Megan 76
Silverman, Bernard 38, 83
Silverstein, Alison 47
Simon, James 95
Simon, Neal 85
Siu, Cynthia 78, 86
Skosnik, Patrick 83
Smith, Alicia 87
Smith, Evan 83, 95
Smith, Thomas 92
Snyder, Gretchen 79, 92
Soares, Jair 20
Sosinsky, Alexandra 84
Southwick, Steven 87
Spencer, Andrea 86
Spencer, Thomas 75, 86, 96
Squires, Liza 75, 86
Stamler, David 89
Stanford, Arielle 95
Steans, Bennett 75
Steans, Tammy 75
Stein, Lisa 94
Stein, Mark 20, 75, 86
Sternat, Tia 71
Stika, Catherine 67
Stowe, Zachary 80
Strickland, Jennifer 75, 86
Stringer, Kathleen 83
Stürmer, Til 78
Such, Pedro 77, 87, 88
Sullivan, Gregory 42, 87
Suppes, Trisha 22
Swardfager, Walter 46
Swartz, Holly A. 17, 18, 21, 29, 39, 65
Syed, Shariful 96
Szabo, Steven 76
Szatmári, Balázs 83
Tafti, Mehdi 85
Tamburri, Paul 84
Tamiz, Amir 13, 64
Teixeira, Antonio 20
Thase, Michael 22, 80, 91
Tiwari, Arun 95
Tocco, Michael 88
Tolliver, Bryan 79, 81
Tong, My-Linh 88
Toure, Juliette 66
Trivedi, Madhukar 18, 22, 37, 59, 79
Tseng, Tina 78
Tulloch, Gabriela 95
Tye, Susannah 91
Umbricht, Daniel 84
Umhau, John 81
Updegraff, Kimberly 57
Valdez, Victoria 31, 96
Valdeheer, Susan 79
Valeri, Linda 93
Van Dam, Nicholas 87
van der Hoop, Roland Gerritsen 76
Vanle, Brigitte 58
Vanover, Kimberly 42, 79, 92
Vasarri, Stefania 80, 89
Vashist, Akshay 92
Vaughan, Adam 78
Velligan, Dawn 37
Verghese, Cherian 94
Verheoff, Paul 80
Vgontzas, Alexandros 75
Vieta, Eduard 83
Viguera, Adele 84
Villarreal, Gerardo 31
Vitiello, Benedetto 18, 21
von Moltke, Lisa 94
Wahlestedt, Claes 87
Walker, Deena 7, 76
Walling, David 94
Walsh, Emily 78
Walton, Kevin 14, 29, 64
Wan, Xiaohai 96
Wang, Changning 87
Wang, Tao 82
Wang, Xingmei 94
Wang, Yaning 40
Ward, Kristen 7, 83
Waschbusch, Daniel 36
Weedon, Jeremy 84
Weiden, Peter 55, 83, 94, 95
Weiller, Emmanuelle 90, 91
Weiss, Holger 76
Weiss, Catherine 90, 91
Wennogle, Lawrence 79, 92
Wilcox, Charles 88
Wilens, Timothy 86
Wilkinson, Samuel 7, 46, 79
Williams, Janet 72, 94
Wilson, Hilary 84
Wisner, Katherine 44, 67
Wojtalik, Jessica 7, 46
Wolanski, Kristy 85
Wood, Steven 92
Wright, Clinton 94
Xia, Hanjing Emily 77
Xiao, Le 78, 89
Xu, Judith 81
Yadav, Sanjay 75
Yang, Fang 45
Yang, Jian 78
Yao, Wei 79
Yatham, Lakshmi 82
Yavorsky, William 85
Yolken, Robert 93
Yost, Jonathan 85
Youngstrom, Eric 91
Younis, Islam 8, 16, 40, 52, 74
Yule, Amy 75
Yurgelun-Todd, Deborah 92
Zai, Clement 95
Zarate, Carlos A. 21, 41, 42, 91
Zarit, Steven 89
Zeier, Zane 87
Zhang, Doris 81
Zhang, Jianping 21, 45
Zhang, Peter 90, 91
Zhao, Cathy 82, 92
Zhong, Wei 80, 91
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou, Jing-jing</td>
<td>78, 89</td>
<td>Zinner, Samuel</td>
<td>86</td>
</tr>
<tr>
<td>Zhu, Hao</td>
<td>40</td>
<td>Zisook, Sidney</td>
<td>22</td>
</tr>
<tr>
<td>Zhu, Xue-quan</td>
<td>78, 89</td>
<td>Zito, Julie</td>
<td>81</td>
</tr>
<tr>
<td>Zimmerman, Mark</td>
<td>47, 78, 88</td>
<td>Zweben, Allen</td>
<td>76</td>
</tr>
</tbody>
</table>
FUTURE ASCP MEETINGS

Fall 2017 Psychopharmacology Update: State-of-the Art Meeting
October 21-22, 2017
The Roosevelt New York, New York

2018 ASCP Annual Meeting
May 28 – June 1, 2018
Loews Miami Beach, Miami Beach, Florida

ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027
phone: 615-649-3085
fax: 888-417-3311
email: info@ascpp.org